|
G |
Ache |
acetylcholinesterase |
affects activity multiple interactions |
EXP |
mancozeb affects the activity of ACHE protein [carbendazim co-treated with mancozeb] results in increased activity of ACHE protein |
CTD |
PMID:10641187 PMID:33217513 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Actg1 |
actin, gamma 1 |
increases expression |
ISO |
mancozeb results in increased expression of ACTG1 protein |
CTD |
PMID:21375462 |
|
NCBI chr10:105,619,738...105,622,587
Ensembl chr10:105,619,737...105,624,232
|
|
G |
Actmap |
actin maturation protease |
decreases expression |
ISO |
mancozeb results in decreased expression of ACTMAP mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:82,490,313...82,499,841
Ensembl chr 1:82,490,363...82,499,841
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein |
CTD |
PMID:19883720 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
decreases expression |
ISO |
mancozeb results in decreased expression of ALB protein |
CTD |
PMID:21375462 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases activity |
EXP |
mancozeb results in decreased activity of ALDH2 protein |
CTD |
PMID:17010440 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases activity |
EXP |
mancozeb results in decreased activity of ALDH5A1 protein |
CTD |
PMID:17010440 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Angptl1 |
angiopoietin-like 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of ANGPTL1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr13:68,963,198...68,969,742
Ensembl chr13:68,962,991...68,992,570
|
|
G |
Anxa2 |
annexin A2 |
decreases expression |
ISO |
mancozeb results in decreased expression of ANXA2 protein |
CTD |
PMID:21375462 |
|
NCBI chr 8:70,105,268...70,141,663
Ensembl chr 8:70,105,253...70,141,658
|
|
G |
Apaf1 |
apoptotic peptidase activating factor 1 |
increases expression |
ISO |
mancozeb results in increased expression of APAF1 protein |
CTD |
PMID:22289270 |
|
NCBI chr 7:25,494,143...25,579,540
Ensembl chr 7:25,494,609...25,579,540
|
|
G |
Ar |
androgen receptor |
multiple interactions decreases expression decreases activity |
ISO |
mancozeb inhibits the reaction [Dihydrotestosterone binds to and results in increased activity of AR protein]; mancozeb inhibits the reaction [Metribolone binds to and results in increased activity of AR protein] mancozeb results in decreased expression of AR mRNA mancozeb results in decreased activity of AR protein |
CTD |
PMID:23871939 PMID:33396126 |
|
NCBI chr X:63,104,771...63,273,934
Ensembl chr X:63,104,771...63,273,925
|
|
G |
Atp1a2 |
ATPase Na+/K+ transporting subunit alpha 2 |
decreases expression |
ISO |
mancozeb results in decreased expression of ATP1A2 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr13:84,729,597...84,754,544
Ensembl chr13:84,729,601...84,754,544
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
ISO |
mancozeb results in increased expression of BAX mRNA; mancozeb results in increased expression of BAX protein lupeol inhibits the reaction [mancozeb results in increased expression of BAX mRNA] |
CTD |
PMID:22289270 PMID:27235710 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions |
ISO EXP |
mancozeb results in decreased expression of BCL2 mRNA; mancozeb results in decreased expression of BCL2 protein lupeol inhibits the reaction [mancozeb results in decreased expression of BCL2 mRNA] alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of BCL2 protein] |
CTD |
PMID:16005924 PMID:22289270 PMID:27235710 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Car3 |
carbonic anhydrase 3 |
increases expression |
ISO |
mancozeb results in increased expression of CAR3 protein |
CTD |
PMID:21375462 |
|
NCBI chr 2:86,770,418...86,780,011
Ensembl chr 2:86,770,420...86,784,280
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions increases cleavage |
ISO |
mancozeb results in increased activity of CASP3 protein Acetylcysteine inhibits the reaction [mancozeb results in increased cleavage of CASP3 protein] mancozeb results in increased cleavage of and results in increased activity of CASP3 protein |
CTD |
PMID:22289270 PMID:22824503 PMID:30037311 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
mancozeb results in increased activity of CASP7 protein |
CTD |
PMID:22824503 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
mancozeb results in increased activity of CASP8 protein |
CTD |
PMID:22289270 PMID:22824503 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions |
ISO |
mancozeb results in increased activity of CASP9 protein mancozeb results in increased cleavage of and results in increased activity of CASP9 protein |
CTD |
PMID:22289270 PMID:22824503 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
multiple interactions decreases activity |
ISO EXP |
Acetylcysteine inhibits the reaction [mancozeb results in decreased activity of CAT protein]; lupeol inhibits the reaction [mancozeb results in decreased activity of CAT protein]; Quercetin inhibits the reaction [mancozeb results in decreased activity of CAT protein] Colforsin inhibits the reaction [mancozeb results in decreased activity of CAT protein] |
CTD |
PMID:23024109 PMID:27235710 PMID:29283200 PMID:30037311 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc106 |
coiled-coil domain containing 106 |
decreases expression |
ISO |
mancozeb results in decreased expression of CCDC106 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:68,779,882...68,791,140
Ensembl chr 1:68,779,882...68,786,846
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions increases expression |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein mancozeb results in increased expression of CCND1 protein |
CTD |
PMID:19883720 PMID:21375462 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Cdc25c |
cell division cycle 25C |
increases phosphorylation |
ISO |
mancozeb results in increased phosphorylation of CDC25C protein |
CTD |
PMID:21375462 |
|
NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,335,834...26,356,185
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of CDKN1A mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cfap126 |
cilia and flagella associated protein 126 |
decreases expression |
ISO |
mancozeb results in decreased expression of CFAP126 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr13:83,526,657...83,542,552
Ensembl chr13:83,526,657...83,542,552
|
|
G |
Cldn16 |
claudin 16 |
decreases expression |
ISO |
mancozeb results in decreased expression of CLDN16 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr11:74,290,298...74,309,588
Ensembl chr11:74,290,298...74,309,588
|
|
G |
Ctf1 |
cardiotrophin 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of CTF1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335
|
|
G |
Cycs |
cytochrome c, somatic |
increases expression |
ISO |
mancozeb results in increased expression of CYCS protein |
CTD |
PMID:27016407 |
|
NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
decreases activity decreases expression |
EXP ISO |
mancozeb results in decreased activity of CYP1A1 protein mancozeb results in decreased expression of CYP1A1 protein |
CTD |
PMID:1946188 PMID:31096615 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp2b3 |
cytochrome P450, family 2, subfamily b, polypeptide 3 |
decreases expression |
ISO |
mancozeb results in decreased expression of CYP2B6 protein |
CTD |
PMID:31096615 |
|
NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of CYP2E1 mRNA |
CTD |
PMID:31096615 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp3a2 |
cytochrome P450, family 3, subfamily a, polypeptide 2 |
decreases expression |
ISO |
mancozeb results in decreased expression of CYP3A4 mRNA; mancozeb results in decreased expression of CYP3A4 protein |
CTD |
PMID:31096615 |
|
NCBI chr12:9,207,986...9,230,038
Ensembl chr12:9,015,383...9,285,008
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
EXP |
mancozeb results in increased expression of DDIT4 protein |
CTD |
PMID:24764117 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Efcab12 |
EF-hand calcium binding domain 12 |
decreases expression |
ISO |
mancozeb results in decreased expression of EFCAB12 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 4:148,869,381...148,892,922
Ensembl chr 4:148,869,387...148,890,560
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
increases phosphorylation |
ISO |
mancozeb results in increased phosphorylation of ELK1 protein |
CTD |
PMID:21375462 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Esr1 |
estrogen receptor 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of ESR1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002
|
|
G |
Esr2 |
estrogen receptor 2 |
decreases expression |
ISO |
mancozeb results in decreased expression of ESR2 mRNA; mancozeb results in decreased expression of ESR2 protein |
CTD |
PMID:33396126 |
|
NCBI chr 6:94,858,438...94,909,630
Ensembl chr 6:94,809,547...94,908,919
|
|
G |
F3 |
coagulation factor III, tissue factor |
increases expression |
ISO |
mancozeb results in increased expression of F3 protein |
CTD |
PMID:25569083 |
|
NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668
|
|
G |
Fas |
Fas cell surface death receptor |
increases expression |
ISO |
mancozeb results in increased expression of FAS protein |
CTD |
PMID:22289270 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Faslg |
Fas ligand |
increases expression |
ISO |
mancozeb results in increased expression of FASLG protein |
CTD |
PMID:22289270 |
|
NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215
|
|
G |
Gadd45a |
growth arrest and DNA-damage-inducible, alpha |
multiple interactions increases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of GADD45A mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115
|
|
G |
Glyatl3 |
glycine-N-acyltransferase-like 3 |
decreases expression |
ISO |
mancozeb results in decreased expression of GLYATL3 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 9:19,984,239...19,994,762
Ensembl chr 9:19,977,302...19,995,650
|
|
G |
Got1 |
glutamic-oxaloacetic transaminase 1 |
affects activity |
EXP |
mancozeb affects the activity of GOT1 protein |
CTD |
PMID:10641187 |
|
NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633
|
|
G |
Gpt |
glutamic--pyruvic transaminase |
affects activity |
EXP |
mancozeb affects the activity of GPT protein |
CTD |
PMID:10641187 |
|
NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
decreases expression multiple interactions |
ISO |
mancozeb results in decreased expression of GPX1 mRNA Acetylcysteine inhibits the reaction [mancozeb results in decreased expression of GPX1 mRNA] |
CTD |
PMID:30037311 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein |
CTD |
PMID:19883720 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases activity |
ISO |
mancozeb results in decreased activity of HDAC3 protein |
CTD |
PMID:21251949 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases activity |
ISO |
mancozeb results in decreased activity of HDAC6 protein |
CTD |
PMID:21251949 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hnrnpm |
heterogeneous nuclear ribonucleoprotein M |
increases expression |
ISO |
mancozeb results in increased expression of HNRNPM protein |
CTD |
PMID:21375462 |
|
NCBI chr 7:14,438,703...14,476,781
Ensembl chr 7:14,438,688...14,476,762
|
|
G |
Ifitm2 |
interferon induced transmembrane protein 2 |
decreases expression |
ISO |
mancozeb results in decreased expression of IFITM2 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:196,051,539...196,052,719
Ensembl chr 1:196,051,537...196,052,741
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] |
CTD |
PMID:15742816 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions |
ISO |
mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein] |
CTD |
PMID:16112155 |
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il2 |
interleukin 2 |
affects expression |
ISO |
mancozeb affects the expression of IL2 protein |
CTD |
PMID:9012323 |
|
NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566
|
|
G |
Itgb3 |
integrin subunit beta 3 |
decreases expression |
ISO |
mancozeb results in decreased expression of ITGB3 mRNA; mancozeb results in decreased expression of ITGB3 protein |
CTD |
PMID:33396126 |
|
NCBI chr10:89,509,917...89,564,679
Ensembl chr10:89,509,989...89,564,679
|
|
G |
Kcnq2 |
potassium voltage-gated channel subfamily Q member 2 |
increases activity |
EXP |
mancozeb results in increased activity of KCNQ2 protein |
CTD |
PMID:23542819 |
|
NCBI chr 3:168,194,776...168,253,831
Ensembl chr 3:168,195,357...168,275,071
|
|
G |
Kiss1 |
KiSS-1 metastasis-suppressor |
affects expression |
EXP |
mancozeb affects the expression of KISS1 mRNA |
CTD |
PMID:23660487 |
|
NCBI chr13:44,774,823...44,780,707
Ensembl chr13:44,774,823...44,780,612
|
|
G |
LOC120094883 |
small nucleolar RNA SNORD82 |
increases expression |
ISO |
mancozeb results in increased expression of SNORD82 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 9:87,004,515...87,004,586
Ensembl chr 9:87,004,515...87,004,586
|
|
G |
Ltb4r2 |
leukotriene B4 receptor 2 |
increases expression |
ISO |
mancozeb results in increased expression of LTB4R2 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr15:29,258,427...29,260,340
Ensembl chr15:29,259,240...29,260,316
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK1 protein]; mancozeb results in increased localization of and results in increased activity of MAPK1 protein |
CTD |
PMID:21375462 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [mancozeb results in increased activity of MAPK3 protein]; mancozeb results in increased localization of and results in increased activity of MAPK3 protein |
CTD |
PMID:21375462 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mdm2 |
MDM2 proto-oncogene |
multiple interactions increases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in increased expression of MDM2 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915
|
|
G |
Muc1 |
mucin 1, cell surface associated |
decreases expression |
ISO |
mancozeb results in decreased expression of MUC1 mRNA; mancozeb results in decreased expression of MUC1 protein |
CTD |
PMID:33396126 |
|
NCBI chr 2:174,635,559...174,640,738
Ensembl chr 2:174,635,995...174,640,733
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions increases expression decreases expression |
ISO EXP |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein mancozeb results in increased expression of MYC protein mancozeb results in decreased expression of MYC protein alpha-Tocopherol inhibits the reaction [mancozeb results in decreased expression of MYC protein] |
CTD |
PMID:16005924 PMID:19883720 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Nhlrc1 |
NHL repeat containing E3 ubiquitin protein ligase 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of NHLRC1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr17:17,674,375...17,675,565
Ensembl chr17:17,674,319...17,677,148
|
|
G |
Nos2 |
nitric oxide synthase 2 |
increases expression multiple interactions |
ISO |
mancozeb results in increased expression of NOS2 mRNA Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOS2 mRNA] |
CTD |
PMID:30037311 |
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox4 |
NADPH oxidase 4 |
multiple interactions increases expression |
ISO |
Acetylcysteine inhibits the reaction [mancozeb results in increased expression of NOX4 mRNA] |
CTD |
PMID:30037311 |
|
NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406
|
|
G |
Odc1 |
ornithine decarboxylase 1 |
increases activity |
ISO |
mancozeb results in increased activity of ODC1 protein |
CTD |
PMID:1733566 |
|
NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440
|
|
G |
Ogg1 |
8-oxoguanine DNA glycosylase |
multiple interactions decreases expression |
ISO |
lupeol inhibits the reaction [mancozeb results in decreased expression of OGG1 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:146,474,750...146,484,766
|
|
G |
Or1s2 |
olfactory receptor family 1 subfamily S member 2 |
increases expression |
ISO |
mancozeb results in increased expression of OR1S1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:210,913,992...210,914,939
Ensembl chr 1:210,911,289...210,915,657
|
|
G |
Pcdhb20 |
protocadherin beta 20 |
decreases expression |
ISO |
mancozeb results in decreased expression of PCDHB14 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr18:29,211,883...29,215,258
Ensembl chr18:29,211,883...29,215,258
|
|
G |
Prdx2 |
peroxiredoxin 2 |
increases expression |
ISO |
mancozeb results in increased expression of PRDX2 protein |
CTD |
PMID:21375462 |
|
NCBI chr19:23,180,927...23,186,217
Ensembl chr19:23,180,930...23,186,194
|
|
G |
Prl |
prolactin |
multiple interactions increases expression |
ISO |
[mancozeb co-treated with imidacloprid] results in increased expression of PRL protein mancozeb results in increased expression of PRL mRNA |
CTD |
PMID:24530807 PMID:33396126 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Ptges |
prostaglandin E synthase |
increases expression decreases expression multiple interactions |
ISO |
mancozeb results in increased expression of PTGES mRNA mancozeb results in decreased expression of PTGES protein lupeol inhibits the reaction [mancozeb results in increased expression of PTGES mRNA] |
CTD |
PMID:27235710 PMID:32446389 |
|
NCBI chr 3:14,177,892...14,189,236
|
|
G |
Ptges3 |
prostaglandin E synthase 3 |
decreases expression |
ISO |
mancozeb results in decreased expression of PTGES3 mRNA |
CTD |
PMID:32446389 |
|
NCBI chr 7:490,698...507,759
Ensembl chr 7:490,656...508,084
|
|
G |
Ptgs2 |
prostaglandin-endoperoxide synthase 2 |
increases expression |
ISO |
mancozeb results in increased expression of PTGS2 protein |
CTD |
PMID:21375462 PMID:32446389 |
|
NCBI chr13:62,164,080...62,169,770
Ensembl chr13:62,163,932...62,172,188
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form |
CTD |
PMID:19883720 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Pvalb |
parvalbumin |
increases expression |
ISO |
mancozeb results in increased expression of PVALB protein |
CTD |
PMID:21375462 |
|
NCBI chr 7:109,772,939...109,787,954
Ensembl chr 7:109,772,593...109,784,561
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
increases phosphorylation affects localization multiple interactions increases localization |
ISO |
mancozeb results in increased phosphorylation of RELA protein mancozeb affects the localization of RELA protein Acetylcysteine inhibits the reaction [mancozeb affects the localization of RELA protein]; lupeol inhibits the reaction [mancozeb affects the localization of RELA protein]; mancozeb inhibits the reaction [Lipopolysaccharides affects the localization of and results in increased activity of RELA protein] mancozeb results in increased localization of RELA protein |
CTD |
PMID:16112155 PMID:21375462 PMID:22289270 PMID:27235710 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
S100a6 |
S100 calcium binding protein A6 |
increases expression |
ISO |
mancozeb results in increased expression of S100A6 protein |
CTD |
PMID:21375462 |
|
NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
increases expression |
ISO |
mancozeb results in increased expression of S100A9 protein |
CTD |
PMID:21375462 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Scx |
scleraxis bHLH transcription factor |
decreases expression |
ISO |
mancozeb results in decreased expression of SCX mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 7:108,176,608...108,178,626
Ensembl chr 7:108,176,608...108,178,626
|
|
G |
Septin11 |
septin 11 |
increases expression |
ISO |
mancozeb results in increased expression of SEPTIN11 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr14:14,844,759...14,990,856
Ensembl chr14:14,844,580...14,990,853
|
|
G |
Serpinf1 |
serpin family F member 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of SERPINF1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646
|
|
G |
Sirt1 |
sirtuin 1 |
decreases activity |
ISO |
mancozeb results in decreased activity of SIRT1 protein |
CTD |
PMID:21251949 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
decreases activity |
ISO |
mancozeb results in decreased activity of SIRT2 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
decreases activity |
ISO |
mancozeb results in decreased activity of SIRT3 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc14a1 |
solute carrier family 14 member 1 (Kidd blood group) |
decreases expression |
ISO |
mancozeb results in decreased expression of SLC14A1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr18:71,565,453...71,608,807
Ensembl chr18:71,565,454...71,595,146
|
|
G |
Slc5a5 |
solute carrier family 5 member 5 |
multiple interactions |
ISO |
mancozeb inhibits the reaction [SLC5A5 protein results in increased uptake of Iodine] |
CTD |
PMID:27979590 |
|
NCBI chr16:18,546,709...18,556,698
Ensembl chr16:18,546,709...18,556,697
|
|
G |
Sod1 |
superoxide dismutase 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of SOD1 protein |
CTD |
PMID:21375462 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sult2b1 |
sulfotransferase family 2B member 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of SULT2B1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:96,200,155...96,261,295
Ensembl chr 1:96,200,156...96,261,295
|
|
G |
Tek |
TEK receptor tyrosine kinase |
increases activity |
ISO |
mancozeb results in increased activity of TEK protein |
CTD |
PMID:21251949 |
|
NCBI chr 5:109,607,077...109,733,805
Ensembl chr 5:109,607,077...109,733,804
|
|
G |
Tgfb1i1 |
transforming growth factor beta 1 induced transcript 1 |
decreases expression |
ISO |
mancozeb results in decreased expression of TGFB1I1 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr 1:182,828,553...182,835,465
Ensembl chr 1:182,828,544...182,837,080
|
|
G |
Tnf |
tumor necrosis factor |
multiple interactions |
ISO |
mancozeb affects the reaction [[Lipopolysaccharides co-treated with IFNG protein] results in increased secretion of TNF protein] mancozeb inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; mancozeb inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; mancozeb inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of TNF protein] |
CTD |
PMID:15742816 PMID:15893782 PMID:16112155 |
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tp53 |
tumor protein p53 |
decreases expression increases expression multiple interactions |
ISO |
mancozeb results in decreased expression of TRP53 mRNA; mancozeb results in decreased expression of TRP53 protein mancozeb results in increased expression of TP53 mRNA lupeol inhibits the reaction [mancozeb results in increased expression of TP53 mRNA] |
CTD |
PMID:22369882 PMID:27235710 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Tpi1 |
triosephosphate isomerase 1 |
increases expression |
ISO |
mancozeb results in increased expression of TPI1 protein |
CTD |
PMID:21375462 |
|
NCBI chr 4:157,615,283...157,618,813
Ensembl chr 4:157,615,386...157,619,541
|
|
G |
Tpo |
thyroid peroxidase |
decreases activity |
EXP |
mancozeb results in decreased activity of TPO protein |
CTD |
PMID:9418944 |
|
NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199
|
|
G |
Tshb |
thyroid stimulating hormone subunit beta |
multiple interactions |
ISO |
[mancozeb co-treated with imidacloprid] results in increased expression of TSHB protein |
CTD |
PMID:24530807 |
|
NCBI chr 2:190,224,676...190,229,559
Ensembl chr 2:190,224,676...190,229,559
|
|
G |
Xrcc1 |
X-ray repair cross complementing 1 |
decreases expression multiple interactions |
ISO |
mancozeb results in decreased expression of XRCC1 mRNA lupeol inhibits the reaction [mancozeb results in decreased expression of XRCC1 mRNA] |
CTD |
PMID:27235710 |
|
NCBI chr 1:80,140,495...80,168,705
Ensembl chr 1:80,141,207...80,168,701
|
|
G |
Zfp358 |
zinc finger protein 358 |
decreases expression |
ISO |
mancozeb results in decreased expression of ZNF358 mRNA |
CTD |
PMID:33396126 |
|
NCBI chr12:1,552,367...1,556,460
Ensembl chr12:1,552,366...1,556,460
|
|
|
G |
Acads |
acyl-CoA dehydrogenase short chain |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ACADS mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr12:41,493,650...41,502,897
Ensembl chr12:41,493,626...41,502,898
|
|
G |
Ache |
acetylcholinesterase |
decreases expression multiple interactions |
EXP ISO |
Maneb results in decreased expression of ACHE protein [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA |
CTD |
PMID:3868355 PMID:23017109 |
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ACO2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Adam22 |
ADAM metallopeptidase domain 22 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ADAM22 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:25,716,055...25,970,932
Ensembl chr 4:25,715,990...25,964,962
|
|
G |
Adgrb1 |
adhesion G protein-coupled receptor B1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ADGRB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 7:106,404,844...106,476,902
Ensembl chr 7:106,404,958...106,476,902
|
|
G |
Adgrg1 |
adhesion G protein-coupled receptor G1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ADGRG1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr19:10,003,963...10,041,122
Ensembl chr19:10,003,975...10,041,108
|
|
G |
Adora1 |
adenosine A1 receptor |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr13:45,658,872...45,695,821
Ensembl chr13:45,658,872...45,695,801
|
|
G |
Ago3 |
argonaute RISC catalytic component 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of AGO3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:138,632,367...138,714,230
Ensembl chr 5:138,639,569...138,714,230
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein; [Paraquat co-treated with Maneb] results in increased expression of AIF1 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of AIF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of AIF1 protein] |
CTD |
PMID:28202386 PMID:32375810 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AKR1B3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of AKT1 protein; [alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of AKT1 protein; [Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of AKT1 mRNA] |
CTD |
PMID:19883720 PMID:23963992 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alas2 |
5'-aminolevulinate synthase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ALAS2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:19,463,146...19,486,526
Ensembl chr X:19,463,171...19,486,519
|
|
G |
Aldh2 |
aldehyde dehydrogenase 2 family member |
decreases activity |
EXP |
Maneb results in decreased activity of ALDH2 protein |
CTD |
PMID:17010440 |
|
NCBI chr12:34,949,549...34,982,527
Ensembl chr12:34,901,219...34,982,521
|
|
G |
Aldh5a1 |
aldehyde dehydrogenase 5 family, member A1 |
decreases activity multiple interactions |
EXP ISO |
Maneb results in decreased activity of ALDH5A1 protein [Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ALDH5A1 mRNA] |
CTD |
PMID:17010440 PMID:23963992 |
|
NCBI chr17:40,132,339...40,158,677
Ensembl chr17:40,130,883...40,158,677
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ALDOC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Amn |
amnion associated transmembrane protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of AMN mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:130,311,372...130,318,815
Ensembl chr 6:130,311,372...130,318,815
|
|
G |
Ap3b2 |
adaptor related protein complex 3 subunit beta 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AP3B2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:135,412,580...135,445,191
Ensembl chr 1:135,412,580...135,445,191
|
|
G |
Ap3d1 |
adaptor related protein complex 3 subunit delta 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of AP3D1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:8,970,249...9,005,651
Ensembl chr 7:8,970,291...9,005,643
|
|
G |
Apbb1 |
amyloid beta precursor protein binding family B member 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:159,896,889...159,920,505
Ensembl chr 1:159,896,880...159,920,627
|
|
G |
Arf3 |
ADP-ribosylation factor 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ARF3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:129,886,082...129,912,022
Ensembl chr 7:129,886,082...129,912,002
|
|
G |
Arg1 |
arginase 1 |
decreases expression multiple interactions |
ISO |
Maneb results in decreased expression of ARG1 mRNA [Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of ARG1 mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ARG1 mRNA] |
CTD |
PMID:29568078 PMID:32194361 PMID:32375810 PMID:34052309 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arnt2 |
aryl hydrocarbon receptor nuclear translocator 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ARNT2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:138,189,940...138,393,153
|
|
G |
Ascl1 |
achaete-scute family bHLH transcription factor 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 7:21,904,153...21,906,003
Ensembl chr 7:21,903,126...21,905,993
|
|
G |
Atg12 |
autophagy related 12 |
multiple interactions |
ISO |
Maneb promotes the reaction [Paraquat results in increased expression of ATG12 protein] |
CTD |
PMID:22292029 |
|
NCBI chr18:39,452,247...39,462,424
Ensembl chr18:39,452,191...39,462,418
|
|
G |
Atp5f1a |
ATP synthase F1 subunit alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP5A1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794
|
|
G |
Atp5mc1 |
ATP synthase membrane subunit c locus 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP5G1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124 Ensembl chr10:81,023,925...81,027,124
|
|
G |
Atp6v0b |
ATPase H+ transporting V0 subunit B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:131,423,384...131,424,900
Ensembl chr 5:131,423,387...131,426,401
|
|
G |
Atp6v0c |
ATPase H+ transporting V0 subunit C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of ATP6V0C mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:13,196,204...13,202,580
Ensembl chr10:13,196,204...13,201,500
|
|
G |
Atp6v1c1 |
ATPase H+ transporting V1 subunit C1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ATP6V1C1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:69,834,464...69,872,278
Ensembl chr 7:69,834,463...69,872,278
|
|
G |
Atp8a2 |
ATPase phospholipid transporting 8A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ATP8A2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr15:33,817,309...34,350,193
Ensembl chr15:33,819,755...34,350,223
|
|
G |
Bad |
BCL2-associated agonist of cell death |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of BAD protein |
CTD |
PMID:15824117 |
|
NCBI chr 1:204,133,502...204,142,829
Ensembl chr 1:204,131,501...204,142,823
|
|
G |
Bak1 |
BCL2-antagonist/killer 1 |
multiple interactions increases expression affects response to substance |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAK1 mRNA] [Paraquat co-treated with Maneb] results in increased expression of BAK1 protein; Maneb inhibits the reaction [BAK1 protein affects the susceptibility to Paraquat]; Paraquat inhibits the reaction [BAK1 protein affects the susceptibility to Maneb] Maneb results in increased expression of BAK1 mRNA; Maneb results in increased expression of BAK1 protein |
CTD |
PMID:18266926 PMID:23963992 |
|
NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of BAX protein; BAX protein affects the susceptibility to [Paraquat co-treated with Maneb] Maneb results in increased expression of BAX protein [Maneb co-treated with Paraquat] results in increased expression of BAX mRNA; [Paraquat co-treated with Maneb] results in increased expression of BAX protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of BAX mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BAX protein] |
CTD |
PMID:15824117 PMID:18266926 PMID:20964710 PMID:23963992 |
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bbc3 |
Bcl-2 binding component 3 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BBC3 protein 3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein]; [Paraquat co-treated with Maneb] results in increased expression of BBC3 protein; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of BBC3 protein] |
CTD |
PMID:18266926 PMID:34897981 |
|
NCBI chr 1:77,013,281...77,022,509
Ensembl chr 1:77,014,543...77,022,509
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
multiple interactions increases expression |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of BCL2 mRNA] Maneb results in increased expression of BCL2 mRNA; Maneb results in increased expression of BCL2 protein |
CTD |
PMID:18266926 PMID:23963992 |
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2a1 |
BCL2-related protein A1 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BCL2A1 mRNA [Paraquat co-treated with Maneb] results in increased expression of BCL2A1 protein |
CTD |
PMID:18266926 |
|
NCBI chr 8:89,716,914...89,724,998
Ensembl chr 8:89,716,914...89,724,998
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of BCL2L1 protein Maneb results in increased expression of BCL2L1 mRNA |
CTD |
PMID:15824117 PMID:18266926 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BCL2L11 protein [Paraquat co-treated with Maneb] results in increased expression of BCL2L11 protein |
CTD |
PMID:18266926 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
multiple interactions |
ISO EXP |
[Maneb co-treated with Paraquat] results in decreased expression of BDNF mRNA [Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA; [Paraquat co-treated with Maneb] results in decreased expression of BDNF protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of BDNF protein] |
CTD |
PMID:23017109 PMID:27460631 PMID:33368748 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BECN1 protein [Paraquat co-treated with Maneb] results in increased expression of BECN1 protein |
CTD |
PMID:22292029 PMID:26884967 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bicd1 |
BICD cargo adaptor 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of BICD1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:182,479,071...182,631,504
Ensembl chr 4:182,479,071...182,627,434
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BID protein [Maneb co-treated with Paraquat] results in increased expression of BID protein |
CTD |
PMID:18266926 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Bik |
BCL2-interacting killer |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of BIK mRNA; Maneb results in increased expression of BIK protein [Paraquat co-treated with Maneb] results in increased expression of BIK protein |
CTD |
PMID:18266926 |
|
NCBI chr 7:114,672,277...114,691,296
Ensembl chr 7:114,672,277...114,691,296
|
|
G |
Bmp2 |
bone morphogenetic protein 2 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
increases expression |
ISO |
Maneb results in increased expression of BNIP3 mRNA; Maneb results in increased expression of BNIP3 protein |
CTD |
PMID:18266926 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bnip3l |
BCL2 interacting protein 3 like |
increases expression |
ISO |
Maneb results in increased expression of BNIP3L mRNA |
CTD |
PMID:18266926 |
|
NCBI chr15:41,174,594...41,197,730
Ensembl chr15:41,174,594...41,197,803
|
|
G |
Brf1 |
BRF1, RNA polymerase III transcription initiation factor subunit |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of BRF1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:132,034,380...132,081,296
Ensembl chr 6:132,037,272...132,081,278
|
|
G |
Cacna1e |
calcium voltage-gated channel subunit alpha1 E |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CACNA1E mRNA |
CTD |
PMID:22563483 |
|
NCBI chr13:66,574,659...67,063,443
Ensembl chr13:66,581,920...66,894,450
|
|
G |
Cacybp |
calcyclin binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CACYBP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:72,437,485...72,447,810
Ensembl chr13:72,437,490...72,450,177
|
|
G |
Calm1 |
calmodulin 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CALM1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 6:119,487,691...119,495,759
Ensembl chr 6:119,487,621...119,498,227
|
|
G |
Calm2 |
calmodulin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CALM2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:7,091,624...7,104,284
Ensembl chr 6:7,091,567...7,104,287
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
multiple interactions |
ISO EXP |
[Paraquat co-treated with Maneb] affects the expression of CAMP mRNA [Paraquat co-treated with Maneb] results in decreased expression of CAMP mRNA |
CTD |
PMID:22563483 PMID:27460631 |
|
NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
|
|
G |
Capn11 |
calpain 11 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CAPN11 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:15,344,059...15,365,604
Ensembl chr 9:15,344,089...15,365,601
|
|
G |
Casp1 |
caspase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein; [Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA; [Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased cleavage of CASP1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP1 mRNA] |
CTD |
PMID:23963992 PMID:32375810 PMID:34052309 |
|
NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383
|
|
G |
Casp3 |
caspase 3 |
increases activity multiple interactions |
ISO |
Maneb results in increased activity of CASP3 protein 3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; [Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP3 protein modified form] |
CTD |
PMID:22824503 PMID:34897981 |
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp7 |
caspase 7 |
increases activity |
ISO |
Maneb results in increased activity of CASP7 protein |
CTD |
PMID:22824503 |
|
NCBI chr 1:255,437,195...255,476,737
Ensembl chr 1:255,437,172...255,476,729
|
|
G |
Casp8 |
caspase 8 |
increases activity |
ISO |
Maneb results in increased activity of CASP8 protein |
CTD |
PMID:22824503 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
multiple interactions increases activity |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA; [Paraquat co-treated with Maneb] results in increased expression of CASP9 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CASP9 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CASP9 protein] Maneb results in increased activity of CASP9 protein |
CTD |
PMID:20964710 PMID:22824503 PMID:23963992 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions |
ISO EXP |
Maneb results in decreased activity of CAT protein [Maneb co-treated with Paraquat] results in increased expression of CAT mRNA |
CTD |
PMID:26210702 PMID:29859004 |
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Ccdc88a |
coiled coil domain containing 88A |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCDC88A mRNA |
CTD |
PMID:22563483 |
|
NCBI chr14:103,104,091...103,256,112
Ensembl chr14:103,103,513...103,252,368
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCL19 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
|
|
G |
Ccl21 |
C-C motif chemokine ligand 21 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CCL21 mRNA; [Paraquat co-treated with Maneb] affects the expression of CCL21A mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:56,980,557...56,981,661
Ensembl chr 5:56,980,558...56,981,686
|
|
G |
Ccnd1 |
cyclin D1 |
multiple interactions |
ISO EXP |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of CCND1 protein [Maneb co-treated with Paraquat] results in decreased expression of CCND1 mRNA |
CTD |
PMID:19883720 PMID:29859004 |
|
NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602
|
|
G |
Ccnd2 |
cyclin D2 |
multiple interactions |
EXP |
[Maneb co-treated with Paraquat] results in decreased expression of CCND2 mRNA |
CTD |
PMID:29859004 |
|
NCBI chr 4:159,966,883...159,989,261
Ensembl chr 4:159,962,363...159,989,495
|
|
G |
Cd34 |
CD34 molecule |
increases expression |
EXP |
Maneb results in increased expression of CD34 |
CTD |
PMID:25803990 |
|
NCBI chr13:106,480,074...106,499,462
Ensembl chr13:106,480,043...106,499,832
|
|
G |
Cd68 |
Cd68 molecule |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CD68 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr10:54,381,814...54,383,693
Ensembl chr10:54,381,815...54,383,697
|
|
G |
Cdhr4 |
cadherin-related family member 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CDHR4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367
|
|
G |
Cdipt |
CDP-diacylglycerol--inositol 3-phosphatidyltransferase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CDIPT mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:181,583,098...181,587,409
Ensembl chr 1:181,583,141...181,587,408
|
|
G |
Cdk2 |
cyclin dependent kinase 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CDK2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403
|
|
G |
Cdk5r1 |
cyclin-dependent kinase 5 regulatory subunit 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:65,484,266...65,485,467
Ensembl chr10:65,483,941...65,488,456
|
|
G |
Cdk5rap1 |
CDK5 regulatory subunit associated protein 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:142,838,081...142,872,669
Ensembl chr 3:142,708,028...142,872,677
|
|
G |
Cdk5rap2 |
CDK5 regulatory subunit associated protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA] |
CTD |
PMID:23017109 |
|
NCBI chr 5:83,792,282...83,961,129
Ensembl chr 5:83,792,284...83,960,782
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDKN1A mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn2a |
cyclin-dependent kinase inhibitor 2A |
multiple interactions increases expression |
EXP |
[Maneb co-treated with Paraquat] results in increased expression of CDKN2A mRNA Maneb results in increased expression of CDKN2A mRNA |
CTD |
PMID:29859004 |
|
NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CEBPD mRNA |
CTD |
PMID:22563483 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Cep290 |
centrosomal protein 290 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CEP290 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:35,310,071...35,399,392
Ensembl chr 7:35,310,199...35,399,392
|
|
G |
Chrm2 |
cholinergic receptor, muscarinic 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 4:65,015,408...65,149,104
Ensembl chr 4:65,014,144...65,149,103
|
|
G |
Chuk |
component of inhibitor of nuclear factor kappa B kinase complex |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of CHUK protein] |
CTD |
PMID:29568078 |
|
NCBI chr 1:242,959,539...242,995,066
Ensembl chr 1:242,959,760...242,995,065
|
|
G |
Cirbp |
cold inducible RNA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CIRBP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:9,533,857...9,538,899
Ensembl chr 7:9,424,178...9,538,818
|
|
G |
Clca1 |
chloride channel accessory 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CLCA1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:233,938,677...233,964,369
Ensembl chr 2:233,938,677...233,964,369
|
|
G |
Clu |
clusterin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CLU mRNA |
CTD |
PMID:18386188 |
|
NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315
|
|
G |
Cope |
COPI coat complex subunit epsilon |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COPE mRNA |
CTD |
PMID:18386188 |
|
NCBI chr16:19,114,871...19,125,527
Ensembl chr16:19,114,871...19,128,907
|
|
G |
Cox5a |
cytochrome c oxidase subunit 5A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX5A protein] |
CTD |
PMID:23562983 |
|
NCBI chr 8:57,922,374...57,933,781
Ensembl chr 8:57,922,290...57,933,781
|
|
G |
Cox6a1 |
cytochrome c oxidase subunit 6A1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX6A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041
|
|
G |
Cox6b1 |
cytochrome c oxidase subunit 6B1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of COX6B1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
|
|
G |
Cox7a2 |
cytochrome c oxidase subunit 7A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633
|
|
G |
Cox7a2l |
cytochrome c oxidase subunit 7A2 like |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of COX7A2L mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:11,184,284...11,198,287
Ensembl chr 6:11,184,285...11,198,273
|
|
G |
Cplx1 |
complexin 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CPLX1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CPLX1 protein |
CTD |
PMID:17532186 |
|
NCBI chr14:1,184,638...1,216,392
|
|
G |
Creb1 |
cAMP responsive element binding protein 1 |
multiple interactions |
ISO EXP |
[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of CREB1 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein; [Paraquat co-treated with Maneb] results in decreased expression of CREB1 protein modified form; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of and results in decreased phosphorylation of CREB1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of CREB1 mRNA] |
CTD |
PMID:23963992 PMID:27460631 PMID:33368748 |
|
NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816
|
|
G |
Crip2 |
cysteine-rich protein 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CRIP2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 6:132,221,120...132,226,066
Ensembl chr 6:132,221,082...132,226,065
|
|
G |
Crlf2 |
cytokine receptor-like factor 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of CRLF2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr14:103,943...108,643
Ensembl chr14:103,939...108,642
|
|
G |
Crot |
carnitine O-octanoyltransferase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CROT mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:25,068,270...25,133,111
Ensembl chr 4:25,080,587...25,133,109
|
|
G |
Csf1r |
colony stimulating factor 1 receptor |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF1R mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr18:54,546,673...54,590,418
Ensembl chr18:54,546,659...54,590,415
|
|
G |
Csf2ra |
colony stimulating factor 2 receptor subunit alpha |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CSF2RA mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr14:98,089...103,261
Ensembl chr14:89,172...103,128
|
|
G |
Ctsl |
cathepsin L |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CTSL mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:764,370...770,533
Ensembl chr17:764,309...770,548
|
|
G |
Cybb |
cytochrome b-245 beta chain |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB mRNA] [Maneb co-treated with Paraquat] results in increased expression of CYBB protein; [Paraquat co-treated with Maneb] results in increased expression of CYBB protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CYBB protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYBB protein] |
CTD |
PMID:29568078 PMID:30797899 PMID:32375810 PMID:34052309 |
|
NCBI chr X:13,360,583...13,392,517
Ensembl chr X:13,359,430...13,392,586
|
|
G |
Cyc1 |
cytochrome c-1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of CYC1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:108,067,106...108,069,483
Ensembl chr 7:108,067,115...108,069,479
|
|
G |
Cyp1a1 |
cytochrome P450, family 1, subfamily a, polypeptide 1 |
increases activity decreases expression increases expression |
EXP ISO |
Maneb results in increased activity of CYP1A1 protein Maneb results in decreased expression of CYP1A1 mRNA Maneb results in increased expression of CYP1A1 mRNA; Maneb results in increased expression of CYP1A1 protein |
CTD |
PMID:20888808 PMID:32194361 |
|
NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125
|
|
G |
Cyp1a2 |
cytochrome P450, family 1, subfamily a, polypeptide 2 |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of CYP1A2 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP1A2 mRNA] |
CTD |
PMID:23159886 |
|
NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312
|
|
G |
Cyp2c6v1 |
cytochrome P450, family 2, subfamily C, polypeptide 6, variant 1 |
decreases expression |
ISO |
Maneb results in decreased expression of CYP2C19 protein |
CTD |
PMID:32194361 |
|
NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596
|
|
G |
Cyp2d4 |
cytochrome P450, family 2, subfamily d, polypeptide 4 |
multiple interactions decreases expression |
ISO |
Ketoconazole inhibits the reaction [Maneb results in decreased expression of CYP2D22 protein] |
CTD |
PMID:22334051 |
|
NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759
|
|
G |
Cyp2e1 |
cytochrome P450, family 2, subfamily e, polypeptide 1 |
decreases activity increases expression multiple interactions increases activity |
EXP ISO |
Maneb results in decreased activity of CYP2E1 protein Maneb results in increased expression of CYP2E1 mRNA; Maneb results in increased expression of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein; [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA]; Maneb results in increased expression of and results in increased activity of CYP2E1 protein; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of and results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [Maneb results in increased expression of CYP2E1 mRNA] Maneb results in increased activity of CYP2E1 protein [Maneb co-treated with Paraquat] results in increased expression of CYP2E1 mRNA; [Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein; [Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of CYP2E1 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of CYP2E1 mRNA] |
CTD |
PMID:11043497 PMID:16510128 PMID:20888808 PMID:20964710 PMID:23159886 |
|
NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023
|
|
G |
Cyp7a1 |
cytochrome P450 family 7 subfamily A member 1 |
decreases expression |
ISO |
Maneb results in decreased expression of CYP7A1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688
|
|
G |
Dap3 |
death associated protein 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DAP3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:174,319,341...174,347,489
Ensembl chr 2:174,318,983...174,346,461
|
|
G |
Dbi |
diazepam binding inhibitor |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of DBI mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:31,241,466...31,249,853
Ensembl chr13:31,206,988...31,268,693
|
|
G |
Ddit4 |
DNA-damage-inducible transcript 4 |
increases expression |
EXP |
Maneb results in increased expression of DDIT4 protein |
CTD |
PMID:24764117 |
|
NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105
|
|
G |
Ddx5 |
DEAD-box helicase 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DDX5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:91,723,508...91,732,210
Ensembl chr10:91,723,508...91,732,283
|
|
G |
Dgki |
diacylglycerol kinase, iota |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DGKI mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:65,420,108...65,872,733
|
|
G |
Dio1 |
iodothyronine deiodinase 1 |
decreases activity |
ISO |
Maneb results in decreased activity of DIO1 protein |
CTD |
PMID:29228274 |
|
NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970
|
|
G |
Dip2b |
disco-interacting protein 2 homolog B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DIP2B mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:131,174,575...131,350,417
Ensembl chr 7:131,174,567...131,349,092
|
|
G |
Dll1 |
delta like canonical Notch ligand 1 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:56,312,062...56,320,177
Ensembl chr 1:56,312,066...56,320,179
|
|
G |
Dlst |
dihydrolipoamide S-succinyltransferase |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of DLST protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of DLST protein] |
CTD |
PMID:23562983 |
|
NCBI chr 6:104,758,511...104,783,296
Ensembl chr 6:104,758,631...104,783,296
|
|
G |
Dmrta2 |
DMRT-like family A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of DMRTA2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:124,805,883...124,811,694
Ensembl chr 5:124,805,883...124,811,630
|
|
G |
Dnajb6 |
DnaJ heat shock protein family (Hsp40) member B6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DNAJB6 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:5,452,683...5,556,679
Ensembl chr 4:5,452,683...5,556,659
|
|
G |
Dnm2 |
dynamin 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of DNM2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:19,978,313...20,060,162
Ensembl chr 8:19,978,400...20,060,157
|
|
G |
Drd2 |
dopamine receptor D2 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 8:49,708,903...49,772,888
Ensembl chr 8:49,708,927...49,772,875
|
|
G |
Drd4 |
dopamine receptor D4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of DRD4 protein |
CTD |
PMID:22563483 |
|
NCBI chr 1:196,396,366...196,400,824
Ensembl chr 1:196,396,366...196,399,553
|
|
G |
Drd5 |
dopamine receptor D5 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr14:72,489,347...72,490,774
Ensembl chr14:72,489,347...72,490,774
|
|
G |
E2f1 |
E2F transcription factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of E2F1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361
|
|
G |
Eef1a1 |
eukaryotic translation elongation factor 1 alpha 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of EEF1A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:79,341,554...79,344,784
Ensembl chr 8:79,341,557...79,344,839
|
|
G |
Eef1g |
eukaryotic translation elongation factor 1 gamma |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EEF1G mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:205,860,713...205,871,319
Ensembl chr 1:205,860,698...205,872,382
|
|
G |
Efnb1 |
ephrin B1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr X:64,257,351...64,270,158
Ensembl chr X:64,257,351...64,270,157
|
|
G |
Egr4 |
early growth response 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of EGR4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328
|
|
G |
Eif4g2 |
eukaryotic translation initiation factor 4, gamma 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of EIF4G2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:165,181,434...165,193,588
|
|
G |
Elk1 |
ETS transcription factor ELK1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ELK1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713
|
|
G |
Eno1 |
enolase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of ENO1 protein; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ENO1 protein] |
CTD |
PMID:17532186 PMID:18386188 PMID:23562983 |
|
NCBI chr 5:160,719,951...160,731,337
Ensembl chr 5:160,719,951...160,731,336
|
|
G |
Eno2 |
enolase 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ENO2 protein |
CTD |
PMID:23562983 |
|
NCBI chr 4:157,572,085...157,580,971
Ensembl chr 4:157,572,088...157,580,980
|
|
G |
Etl4 |
enhancer trap locus 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ETL4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:82,841,075...83,304,868
Ensembl chr17:82,495,041...83,304,715
|
|
G |
Fas |
Fas cell surface death receptor |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FAS mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591
|
|
G |
Fez1 |
fasciculation and elongation protein zeta 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 8:36,544,462...36,589,684
Ensembl chr 8:36,544,535...36,589,683
|
|
G |
Fgfr3 |
fibroblast growth factor receptor 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FGFR3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:76,987,242...77,002,671
Ensembl chr14:76,987,993...77,003,341
|
|
G |
Fkbp4 |
FKBP prolyl isomerase 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FKBP4 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:161,703,379...161,711,833
Ensembl chr 4:161,703,379...161,711,833
|
|
G |
Fkbp5 |
FKBP prolyl isomerase 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FKBP5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674
|
|
G |
Fos |
Fos proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
ISO EXP |
[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of FOS mRNA] [Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA; [Paraquat co-treated with Maneb] results in decreased expression of FOS protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of FOS protein] |
CTD |
PMID:23963992 PMID:27460631 PMID:33368748 |
|
NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036
|
|
G |
Fxyd6 |
FXYD domain-containing ion transport regulator 6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of FXYD6 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:45,679,054...45,705,958
Ensembl chr 8:45,678,885...45,705,958
|
|
G |
G6pc1 |
glucose-6-phosphatase catalytic subunit 1 |
decreases expression |
ISO |
Maneb results in decreased expression of G6PC1 mRNA |
CTD |
PMID:32194361 |
|
NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804
|
|
G |
Gabra6 |
gamma-aminobutyric acid type A receptor subunit alpha6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GABRA6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:26,810,411...26,825,768
Ensembl chr10:26,810,423...26,825,769
|
|
G |
Gas5 |
growth arrest specific 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GAS5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:73,303,611...73,306,932
|
|
G |
Gclc |
glutamate-cysteine ligase, catalytic subunit |
increases expression increases activity |
ISO EXP |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA Maneb results in increased activity of GCLC protein |
CTD |
PMID:15527874 PMID:21402726 |
|
NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544
|
|
G |
Gfap |
glial fibrillary acidic protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of GFAP protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of GFAP protein] |
CTD |
PMID:30797899 |
|
NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589
|
|
G |
Gh1 |
growth hormone 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GH mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078
|
|
G |
Gm2a |
ganglioside GM2 activator |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GM2A mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:39,219,221...39,231,756
Ensembl chr10:39,219,243...39,231,757
|
|
G |
Gmfb |
glia maturation factor, beta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GMFB mRNA; [Paraquat co-treated with Maneb] results in decreased expression of GMFB protein |
CTD |
PMID:17532186 |
|
NCBI chr15:20,069,923...20,081,005
Ensembl chr15:20,067,263...20,080,331
|
|
G |
Gng5 |
G protein subunit gamma 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GNG5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:235,394,680...235,403,177
Ensembl chr 1:77,292,043...77,292,513
|
|
G |
Gngt2 |
G protein subunit gamma transducin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GNGT2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:80,776,003...80,784,235
|
|
G |
Gpr27 |
G protein-coupled receptor 27 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of GPR27 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 4:132,328,364...132,329,497
Ensembl chr 4:132,328,364...132,329,497
|
|
G |
Gpx1 |
glutathione peroxidase 1 |
multiple interactions decreases expression |
ISO EXP |
GPX1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of GPX1 mRNA Maneb results in decreased expression of GPX1 mRNA |
CTD |
PMID:15824117 PMID:26210702 PMID:29859004 |
|
NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024
|
|
G |
Gpx4 |
glutathione peroxidase 4 |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of GPX4 mRNA [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein [Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of GPX4 protein]; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA] |
CTD |
PMID:23764462 PMID:30797899 |
|
NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982
|
|
G |
Grb2 |
growth factor receptor bound protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GRB2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:100,881,404...100,949,193
Ensembl chr10:100,869,718...100,949,309
|
|
G |
Gsk3b |
glycogen synthase kinase 3 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] affects the phosphorylation of GSK3B protein |
CTD |
PMID:19883720 |
|
NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646
|
|
G |
Gsr |
glutathione-disulfide reductase |
multiple interactions |
EXP ISO |
[Acetylcysteine co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Maneb] results in increased activity of GSR protein; [Silymarin co-treated with Paraquat co-treated with Maneb] results in increased activity of GSR protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein |
CTD |
PMID:23159886 PMID:23764462 |
|
NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661
|
|
G |
Gsta3 |
glutathione S-transferase alpha 3 |
increases expression |
EXP |
Maneb results in increased expression of GSTA3 mRNA |
CTD |
PMID:20888808 |
|
NCBI chr 9:23,658,574...23,684,240
Ensembl chr 9:23,658,574...23,684,240
|
|
G |
Gsta4 |
glutathione S-transferase alpha 4 |
multiple interactions increases activity increases expression |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein; [Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Acetylcysteine promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Acetylcysteine promotes the reaction [Maneb results in increased expression of GSTA4 mRNA]; Maneb results in increased expression of and results in increased activity of GSTA4 protein; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [[Paraquat co-treated with Maneb] results in increased expression of GSTA4 mRNA]; Silymarin promotes the reaction [Maneb results in increased expression of and results in increased activity of GSTA4 protein]; Silymarin promotes the reaction [Maneb results in increased expression of GSTA4 mRNA] Maneb results in increased activity of GSTA4 protein Maneb results in increased expression of GSTA4 mRNA; Maneb results in increased expression of GSTA4 protein |
CTD |
PMID:20888808 PMID:23159886 |
|
NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182
|
|
G |
Gstp1 |
glutathione S-transferase pi 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of GSTP1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226
|
|
G |
Guk1 |
guanylate kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of GUK1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:43,971,514...43,988,658
Ensembl chr10:43,971,509...43,980,107
|
|
G |
H2ac20 |
H2A clustered histone 20 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of H2AC20 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:183,779,879...183,780,324
|
|
G |
H2bc9 |
H2B clustered histone 9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of H2BC9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:42,470,593...42,478,605
|
|
G |
Hba-a1 |
hemoglobin alpha, adult chain 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HBA-A1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:15,337,265...15,338,121
Ensembl chr10:15,307,815...15,338,392
|
|
G |
Hdac3 |
histone deacetylase 3 |
decreases activity |
ISO |
Maneb results in decreased activity of HDAC3 protein |
CTD |
PMID:21251949 |
|
NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856
|
|
G |
Hdac6 |
histone deacetylase 6 |
decreases activity |
ISO |
Maneb results in decreased activity of HDAC6 protein |
CTD |
PMID:21251949 |
|
NCBI chr X:14,550,645...14,572,445
Ensembl chr X:14,551,044...14,572,441
|
|
G |
Hes3 |
hes family bHLH transcription factor 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of HES3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:162,793,611...162,799,578
Ensembl chr 5:162,794,367...162,796,261
|
|
G |
Hey2 |
hes-related family bHLH transcription factor with YRPW motif 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:26,822,131...26,832,218
|
|
G |
Heyl |
hes-related family bHLH transcription factor with YRPW motif-like |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 5:135,508,160...135,525,152
Ensembl chr 5:135,508,160...135,525,152
|
|
G |
Hk1 |
hexokinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HK1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:30,230,488...30,332,161
Ensembl chr20:30,230,486...30,332,131
|
|
G |
Hmga2 |
high mobility group AT-hook 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HMGA2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:55,877,145...55,998,813
Ensembl chr 7:55,880,112...55,994,784
|
|
G |
Hmgn5 |
high mobility group nucleosome binding domain 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of HMGN5 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:74,085,871...74,094,488
|
|
G |
Hmox1 |
heme oxygenase 1 |
increases expression multiple interactions |
EXP ISO |
Maneb results in increased expression of HMOX1 protein [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein |
CTD |
PMID:15527874 PMID:23764462 |
|
NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079
|
|
G |
Hnrnpk |
heterogeneous nuclear ribonucleoprotein K |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of HNRNPK mRNA |
CTD |
PMID:18386188 |
|
NCBI chr17:6,262,936...6,275,001
Ensembl chr17:6,262,998...6,274,997
|
|
G |
Hsd11b2 |
hydroxysteroid 11-beta dehydrogenase 2 |
decreases activity |
ISO |
Maneb results in decreased activity of HSD11B2 protein |
CTD |
PMID:22796344 |
|
NCBI chr19:33,397,656...33,402,899
Ensembl chr19:33,397,656...33,402,899
|
|
G |
Hsf1 |
heat shock transcription factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSF1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011
|
|
G |
Hsp90aa1 |
heat shock protein 90 alpha family class A member 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA; [Paraquat co-treated with Maneb] results in increased expression of HSP90AA1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSP90AA1 mRNA] |
CTD |
PMID:18386188 PMID:23963992 |
|
NCBI chr 6:129,702,376...129,707,907
Ensembl chr 6:129,702,383...129,707,268
|
|
G |
Hspa1a |
heat shock protein family A (Hsp70) member 1A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of HSPA1B mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:3,855,104...3,859,148
Ensembl chr20:3,856,006...3,873,240
|
|
G |
Hspa5 |
heat shock protein family A (Hsp70) member 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of HSPA5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891
|
|
G |
Hspa8 |
heat shock protein family A (Hsp70) member 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of HSPA8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259
|
|
G |
Icam1 |
intercellular adhesion molecule 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM1 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr 8:19,553,063...19,565,438
Ensembl chr 8:19,553,645...19,565,438
|
|
G |
Icam2 |
intercellular adhesion molecule 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ICAM2 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr10:91,308,608...91,319,536
Ensembl chr10:91,308,538...91,315,293
|
|
G |
Idh3a |
isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IDH3A protein] |
CTD |
PMID:23562983 |
|
NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:54,971,740...54,991,084
|
|
G |
Ier5l |
immediate early response 5-like |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of IER5L mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:13,744,056...13,745,647
Ensembl chr 3:13,744,078...13,745,647
|
|
G |
Ifng |
interferon gamma |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IFNG mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375
|
|
G |
Igf1 |
insulin-like growth factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IGF1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296
|
|
G |
Il1b |
interleukin 1 beta |
multiple interactions increases expression |
EXP ISO |
[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of IL1B mRNA] [Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA; [Maneb co-treated with Paraquat] results in increased expression of IL1B protein; [Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA; [Paraquat co-treated with Maneb] results in increased expression of IL1B protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of IL1B mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA] |
CTD |
PMID:23159886 PMID:23963992 PMID:29568078 PMID:32169474 PMID:32375810 PMID:34052309 More...
|
|
NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415
|
|
G |
Il6 |
interleukin 6 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL6 mRNA] |
CTD |
PMID:32169474 |
|
NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178
|
|
G |
Inhba |
inhibin subunit beta A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of INHBA mRNA; [Paraquat co-treated with Maneb] affects the expression of INHBA mRNA |
CTD |
PMID:22563483 PMID:23017109 |
|
NCBI chr17:49,091,635...49,111,573
Ensembl chr17:49,095,920...49,108,982
|
|
G |
Irs2 |
insulin receptor substrate 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of IRS2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr16:78,488,249...78,512,482
Ensembl chr16:78,485,045...78,512,482
|
|
G |
Itgam |
integrin subunit alpha M |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein; [Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA; [Paraquat co-treated with Maneb] results in increased expression of ITGAM protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of ITGAM protein]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased cleavage of CASP1 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of IL1B protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of ITGAM mRNA] |
CTD |
PMID:28202386 PMID:30797899 PMID:32169474 PMID:32375810 |
|
NCBI chr 1:182,659,047...182,709,495
Ensembl chr 1:182,659,000...182,709,503
|
|
G |
Itgb8 |
integrin subunit beta 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ITGB8 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:140,124,997...140,208,254
Ensembl chr 6:140,127,203...140,208,476
|
|
G |
Itpr1 |
inositol 1,4,5-trisphosphate receptor, type 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of ITPR1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491
|
|
G |
Jpt1 |
Jupiter microtubule associated homolog 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of JPT1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:100,744,468...100,762,504
Ensembl chr10:100,686,797...100,784,513
|
|
G |
Jun |
Jun proto-oncogene, AP-1 transcription factor subunit |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA; [Paraquat co-treated with Maneb] results in decreased expression of JUN protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of JUN protein] |
CTD |
PMID:27460631 PMID:33368748 |
|
NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656
|
|
G |
Kcna2 |
potassium voltage-gated channel subfamily A member 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KCNA2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:194,704,555...194,718,387
Ensembl chr 2:194,704,639...194,718,400
|
|
G |
Kcnma1 |
potassium calcium-activated channel subfamily M alpha 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KCNMA1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr15:302,078...1,001,198
Ensembl chr15:302,214...1,001,198
|
|
G |
Kif1b |
kinesin family member 1B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KIF1B mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:159,607,697...159,742,778
Ensembl chr 5:159,561,271...159,742,778
|
|
G |
Kit |
KIT proto-oncogene receptor tyrosine kinase |
decreases expression |
EXP |
Maneb results in decreased expression of KIT |
CTD |
PMID:25803990 |
|
NCBI chr14:32,547,459...32,624,694
Ensembl chr14:32,548,877...32,624,652
|
|
G |
Klf2 |
KLF transcription factor 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KLF2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr16:17,521,773...17,523,723
Ensembl chr16:17,514,552...17,523,944
|
|
G |
Klhl15 |
kelch-like family member 15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of KLHL15 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr X:58,994,726...59,050,207
Ensembl chr X:58,995,461...59,046,069
|
|
G |
Lamc2 |
laminin subunit gamma 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LAMC2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr13:65,284,664...65,344,200
Ensembl chr13:65,284,664...65,344,200
|
|
G |
Lifr |
LIF receptor subunit alpha |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LIFR mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:56,250,120...56,286,699
|
|
G |
Limk2 |
LIM domain kinase 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LIMK2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr14:78,208,182...78,286,106
Ensembl chr14:78,218,063...78,286,007
|
|
G |
Loricrin |
loricrin cornified envelope precursor protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LOR mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:177,558,062...177,559,980
Ensembl chr 2:177,558,252...177,559,807
|
|
G |
Lrp4 |
LDL receptor related protein 4 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of LRP4 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:77,429,600...77,483,593
Ensembl chr 3:77,429,798...77,483,593
|
|
G |
Lrrc17 |
leucine rich repeat containing 17 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LRRC17 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:13,501,436...13,531,845
|
|
G |
Lrrc41 |
leucine rich repeat containing 41 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LRRC41 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:129,554,547...129,575,450
Ensembl chr 5:129,554,547...129,575,449
|
|
G |
Lrrk2 |
leucine-rich repeat kinase 2 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of ACHE mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5R1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CDK5RAP1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of CHRM2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of EFNB1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of FEZ1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEY2 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA; [LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; LRRK2 protein mutant form inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA] 3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; [Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of LRRK2 protein] |
CTD |
PMID:23017109 PMID:34897981 |
|
NCBI chr 7:122,826,712...122,987,711
Ensembl chr 7:122,826,696...122,987,703
|
|
G |
Lynx1 |
Ly6/neurotoxin 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of LYNX1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:106,632,800...106,638,003
Ensembl chr 7:106,632,797...106,638,023
|
|
G |
Macf1 |
microtubule-actin crosslinking factor 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MACF1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:135,623,729...135,949,097
Ensembl chr 5:135,623,742...135,945,905
|
|
G |
Map2 |
microtubule-associated protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809
|
|
G |
Map2k1 |
mitogen activated protein kinase kinase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAP2K1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:64,683,449...64,754,900
Ensembl chr 8:64,683,449...64,755,147
|
|
G |
Map2k6 |
mitogen-activated protein kinase kinase 6 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of MAP2K6 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:95,373,304...95,490,406
Ensembl chr10:95,373,204...95,488,293
|
|
G |
Mapk1 |
mitogen activated protein kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK1 protein] |
CTD |
PMID:15824117 PMID:30797899 |
|
NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616
|
|
G |
Mapk15 |
mitogen-activated protein kinase 15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MAPK15 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:107,694,907...107,714,640
Ensembl chr 7:107,694,964...107,714,645
|
|
G |
Mapk3 |
mitogen activated protein kinase 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein [Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of MAPK3 protein] |
CTD |
PMID:15824117 PMID:30797899 |
|
NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863
|
|
G |
Mapt |
microtubule-associated protein tau |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of MAPT mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:89,138,644...89,236,137
Ensembl chr10:89,138,627...89,236,129
|
|
G |
Marchf9 |
membrane associated ring-CH-type finger 9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MARCHF9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:62,879,017...62,882,495
Ensembl chr 7:62,879,018...62,882,495
|
|
G |
Mbd3 |
methyl-CpG binding domain protein 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MBD3 mRNA; [Paraquat co-treated with Maneb] results in increased expression of MBD3 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:9,312,961...9,320,166
Ensembl chr 7:9,313,098...9,320,165
|
|
G |
Mbnl1 |
muscleblind-like splicing regulator 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of MBNL1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:144,639,819...144,814,395
Ensembl chr 2:144,670,285...144,814,368
|
|
G |
Mboat2 |
membrane bound O-acyltransferase domain containing 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MBOAT2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:41,471,135...41,597,599
Ensembl chr 6:41,471,161...41,593,485
|
|
G |
Mcl1 |
MCL1 apoptosis regulator, BCL2 family member |
increases expression multiple interactions |
ISO |
Maneb results in increased expression of MCL1 protein [Paraquat co-treated with Maneb] results in increased expression of MCL1 protein |
CTD |
PMID:18266926 |
|
NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303
|
|
G |
Mdm4 |
MDM4 regulator of p53 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MDM4 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:44,432,596...44,516,165
Ensembl chr13:44,406,213...44,474,226
|
|
G |
Mef2c |
myocyte enhancer factor 2C |
multiple interactions |
ISO |
[Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein |
CTD |
PMID:24290359 |
|
NCBI chr 2:13,973,299...14,136,065
Ensembl chr 2:13,993,438...14,132,880
|
|
G |
Mfge8 |
milk fat globule EGF and factor V/VIII domain containing |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MFGE8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073
|
|
G |
Mrc1 |
mannose receptor, C type 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of MRC1 mRNA |
CTD |
PMID:29568078 |
|
NCBI chr17:77,249,187...77,330,857
Ensembl chr17:77,249,187...77,330,857
|
|
G |
Mrpl15 |
mitochondrial ribosomal protein L15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MRPL15 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:14,729,966...14,741,276
Ensembl chr 5:14,729,979...14,741,276
|
|
G |
Mrtfb |
myocardin related transcription factor B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MRTFB mRNA |
CTD |
PMID:22563483 |
|
NCBI chr10:1,116,315...1,278,106
Ensembl chr10:1,116,310...1,277,897
|
|
G |
Mthfr |
methylenetetrahydrofolate reductase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of MTHFR mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:158,465,248...158,484,999
Ensembl chr 5:158,465,296...158,483,797
|
|
G |
Mtor |
mechanistic target of rapamycin kinase |
multiple interactions increases expression |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of MTOR protein; Maneb promotes the reaction [Paraquat results in increased expression of MTOR protein]; Paraquat promotes the reaction [Maneb results in increased expression of MTOR protein] |
CTD |
PMID:22292029 PMID:26884967 |
|
NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311
|
|
G |
Muc6 |
mucin 6, oligomeric mucus/gel-forming |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of MUC6 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:196,726,678...196,764,842
Ensembl chr 1:196,726,807...196,764,842
|
|
G |
Myc |
MYC proto-oncogene, bHLH transcription factor |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in increased expression of MYC protein |
CTD |
PMID:19883720 |
|
NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630
|
|
G |
Ncf1 |
neutrophil cytosolic factor 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] affects the localization of NCF1 protein; [Maneb co-treated with Paraquat] results in increased expression of NCF1 protein; [Paraquat co-treated with Maneb] results in increased expression of NCF1 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NCF1 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] affects the localization of NCF1 protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NCF1 protein] |
CTD |
PMID:28202386 PMID:29568078 PMID:32375810 PMID:34052309 |
|
NCBI chr12:22,485,382...22,494,647
Ensembl chr12:22,485,451...22,494,646
|
|
G |
Ndp |
norrin cystine knot growth factor NDP |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NDP mRNA |
CTD |
PMID:23017109 |
|
NCBI chr X:5,796,487...5,820,934
Ensembl chr X:5,796,487...5,820,934
|
|
G |
Neurod1 |
neuronal differentiation 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of NEUROD1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:64,360,222...64,363,526
Ensembl chr 3:64,359,395...64,363,649
|
|
G |
Nfat5 |
nuclear factor of activated T-cells 5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NFAT5 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr19:35,199,737...35,286,675
Ensembl chr19:35,199,016...35,286,675
|
|
G |
Nfe2l2 |
NFE2 like bZIP transcription factor 2 |
increases expression increases response to substance multiple interactions |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of GCLC mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA; [Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA; Maneb results in increased expression of NFE2L2 protein NFE2L2 gene mutant form results in increased susceptibility to Maneb [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased abundance of Glutathione; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of GSR protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in decreased expression of HMOX1 protein; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Manganese; [NFE2L2 gene mutant form results in increased susceptibility to Maneb] which results in increased abundance of Thiobarbituric Acid Reactive Substances; NFE2L2 gene mutant form inhibits the reaction [Maneb results in increased expression of GPX4 mRNA] |
CTD |
PMID:21402726 PMID:23764462 |
|
NCBI chr 3:60,594,239...60,621,785
Ensembl chr 3:60,594,242...60,621,737
|
|
G |
Nfib |
nuclear factor I/B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NFIB mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:96,759,208...96,973,092
Ensembl chr 5:96,764,653...96,975,479
|
|
G |
Nfkb1 |
nuclear factor kappa B subunit 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NFKB1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404
|
|
G |
Nfkbia |
NFKB inhibitor alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein; [Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of and results in decreased expression of NFKBIA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased degradation of and results in increased phosphorylation of NFKBIA protein] |
CTD |
PMID:28202386 PMID:29568078 |
|
NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941
|
|
G |
Nipbl |
NIPBL, cohesin loading factor |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NIPBL mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:57,399,443...57,586,770
Ensembl chr 2:57,399,445...57,565,899
|
|
G |
Nlrp3 |
NLR family, pyrin domain containing 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein; [Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NLRP3 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of NLRP3 protein] |
CTD |
PMID:32375810 PMID:34052309 |
|
NCBI chr10:44,326,770...44,353,814
Ensembl chr10:44,328,566...44,352,811
|
|
G |
Nog |
noggin |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of NOG mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:74,128,712...74,130,339
Ensembl chr10:74,128,712...74,130,339
|
|
G |
Nos2 |
nitric oxide synthase 2 |
multiple interactions increases expression |
ISO EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; [Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA; [Maneb co-treated with Paraquat] results in increased expression of NOS2 protein; [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; [Paraquat co-treated with Maneb] results in increased expression of NOS2 protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 protein]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of NOS2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA] [Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOS2 mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of NOS2 mRNA] |
CTD |
PMID:20455021 PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 PMID:32375810 PMID:34052309 More...
|
|
NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210
|
|
G |
Nox1 |
NADPH oxidase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA]; diphenyleneiodonium inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of NOX1 mRNA] |
CTD |
PMID:30797899 |
|
NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236
|
|
G |
Nps |
neuropeptide S |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NPS mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:190,077,040...190,080,821
Ensembl chr 1:190,077,040...190,080,821
|
|
G |
Nqo1 |
NAD(P)H quinone dehydrogenase 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of NQO1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557
|
|
G |
Nr4a1 |
nuclear receptor subfamily 4, group A, member 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NR4A1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:132,368,399...132,389,300
Ensembl chr 7:132,374,840...132,389,297
|
|
G |
Nr4a2 |
nuclear receptor subfamily 4, group A, member 2 |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of NR4A2 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of NR4A2 protein |
CTD |
PMID:29152652 |
|
NCBI chr 3:41,689,847...41,707,036
Ensembl chr 3:41,689,851...41,697,877
|
|
G |
Nrg1 |
neuregulin 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NRG1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr16:59,250,658...60,303,024
Ensembl chr16:59,250,854...60,296,884
|
|
G |
Nrtn |
neurturin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of NRTN mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:1,581,860...1,587,835
Ensembl chr 9:1,581,975...1,583,102
|
|
G |
Ntn1 |
netrin 1 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA; [Maneb co-treated with Paraquat] results in decreased expression of NTN1 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr10:52,899,933...53,098,591
Ensembl chr10:52,899,934...53,085,326
|
|
G |
Ntrk2 |
neurotrophic receptor tyrosine kinase 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of NTRK2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:5,558,992...5,870,299
Ensembl chr17:5,559,043...5,869,136
|
|
G |
Oaz2 |
ornithine decarboxylase antizyme 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of OAZ2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:66,199,694...66,213,513
Ensembl chr 8:66,199,706...66,231,453
|
|
G |
P2ry4 |
pyrimidinergic receptor P2Y4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of P2RY4 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr X:65,681,680...65,717,404
Ensembl chr X:65,683,232...65,721,748
|
|
G |
Park7 |
Parkinsonism associated deglycase |
multiple interactions |
ISO |
3-(4-(morpholin-4-yl)-7H-pyrrolo(2,3-d)pyrimidin-5-yl)benzonitrile inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; [Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein]; Plant Extracts inhibits the reaction [[Paraquat co-treated with Maneb] results in increased oxidation of PARK7 protein] |
CTD |
PMID:34897981 |
|
NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970
|
|
G |
Pax5 |
paired box 5 |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 5:58,763,334...58,945,719
Ensembl chr 5:58,765,036...58,944,326
|
|
G |
Pax6 |
paired box 6 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX6 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 3:92,128,772...92,157,022
Ensembl chr 3:92,135,637...92,157,014
|
|
G |
Pcdh7 |
protocadherin 7 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PCDH7 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:52,471,801...52,901,696
Ensembl chr14:52,475,610...52,902,051 Ensembl chr14:52,475,610...52,902,051
|
|
G |
Pcna |
proliferating cell nuclear antigen |
multiple interactions |
ISO |
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PCNA protein]; [Paraquat co-treated with Maneb] results in decreased expression of PCNA protein |
CTD |
PMID:23985028 |
|
NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995
|
|
G |
Pcp2 |
Purkinje cell protein 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PCP2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr12:1,681,659...1,683,899
Ensembl chr12:1,681,659...1,683,899
|
|
G |
Pdcd10 |
programmed cell death 10 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of PDCD10 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:160,303,465...160,346,086
Ensembl chr 2:160,303,449...160,346,018
|
|
G |
Pde1b |
phosphodiesterase 1B |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDE1B mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 7:134,627,378...134,654,581
Ensembl chr 7:134,627,322...134,654,580
|
|
G |
Pdgfra |
platelet derived growth factor receptor alpha |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDGFRA mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr14:33,005,838...33,054,347
Ensembl chr14:33,005,839...33,054,335
|
|
G |
Pdha1 |
pyruvate dehydrogenase E1 subunit alpha 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA; [Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PDHA1 protein]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PDHA1 mRNA] |
CTD |
PMID:23562983 PMID:23963992 |
|
NCBI chr X:34,700,481...34,714,309
Ensembl chr X:34,700,409...34,714,311
|
|
G |
Pdyn |
prodynorphin |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of PDYN |
CTD |
PMID:24376148 |
|
NCBI chr 3:116,900,990...116,913,334
Ensembl chr 3:116,900,992...116,913,334
|
|
G |
Pebp1 |
phosphatidylethanolamine binding protein 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PEBP1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr12:39,302,864...39,307,064
Ensembl chr12:39,302,840...39,307,862
|
|
G |
Pgs1 |
phosphatidylglycerophosphate synthase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of PGS1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr10:103,214,635...103,250,254
Ensembl chr10:103,214,646...103,250,254
|
|
G |
Pigc |
phosphatidylinositol glycan anchor biosynthesis, class C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of PIGC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:74,343,619...74,346,148
Ensembl chr13:74,296,854...74,346,211
|
|
G |
Plce1 |
phospholipase C, epsilon 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PLCE1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:236,243,445...236,552,571
Ensembl chr 1:236,244,683...236,551,438
|
|
G |
Pmaip1 |
phorbol-12-myristate-13-acetate-induced protein 1 |
increases expression |
ISO |
Maneb results in increased expression of PMAIP1 mRNA; Maneb results in increased expression of PMAIP1 protein |
CTD |
PMID:18266926 |
|
NCBI chr18:59,986,187...59,990,174
Ensembl chr18:59,986,017...59,992,429
|
|
G |
Pnoc |
prepronociceptin |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of PNOC |
CTD |
PMID:24376148 |
|
NCBI chr15:39,624,635...39,652,463
Ensembl chr15:39,624,641...39,651,867
|
|
G |
Polr1c |
RNA polymerase I and III subunit C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of POLR1C mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 9:14,735,740...14,739,852
Ensembl chr 9:14,735,714...14,739,852
|
|
G |
Polr2k |
RNA polymerase II, I and III subunit K |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of POLR2K mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:67,347,118...67,359,466
Ensembl chr 7:67,356,113...67,357,668
|
|
G |
Pou3f3 |
POU class 3 homeobox 3 |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of POU3F3 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 9:44,945,872...44,948,986
Ensembl chr 9:44,945,872...44,948,992
|
|
G |
Prdx1 |
peroxiredoxin 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of PRDX1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr 5:130,147,276...130,162,850
Ensembl chr 5:130,147,204...130,162,856
|
|
G |
Prdx3 |
peroxiredoxin 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PRDX3 protein] |
CTD |
PMID:23562983 |
|
NCBI chr 1:260,001,642...260,014,064
Ensembl chr 1:260,001,637...260,014,111
|
|
G |
Prkaca |
protein kinase cAMP-activated catalytic subunit alpha |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA; [Paraquat co-treated with Maneb] results in decreased expression of PRKACA protein; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of PRKACA mRNA] |
CTD |
PMID:27460631 PMID:33368748 |
|
NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430
|
|
G |
Prkcz |
protein kinase C, zeta |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of PRKCZ mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:165,817,786...165,930,386
Ensembl chr 5:165,819,466...165,930,367
|
|
G |
Prkn |
parkin RBR E3 ubiquitin protein ligase |
multiple interactions |
ISO |
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein]; [Paraquat co-treated with Maneb] results in increased expression of PRKN protein; [Paraquat co-treated with Maneb] results in increased nitrosation of PRKN protein |
CTD |
PMID:22563483 PMID:23985028 |
|
NCBI chr 1:48,688,651...49,882,520
Ensembl chr 1:48,690,556...49,882,555
|
|
G |
Prl |
prolactin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PRL mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:37,859,999...37,870,062
Ensembl chr17:37,860,007...37,870,062
|
|
G |
Prr7 |
proline rich 7 (synaptic) |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of PRR7 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr17:9,164,375...9,173,669
Ensembl chr17:9,165,269...9,172,536
|
|
G |
Psap |
prosaposin |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of PSAP mRNA |
CTD |
PMID:18386188 |
|
NCBI chr20:28,214,229...28,240,501
Ensembl chr20:28,214,271...28,240,498
|
|
G |
Psen1 |
presenilin 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of PSEN1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 6:103,323,014...103,375,088
Ensembl chr 6:103,323,120...103,371,650
|
|
G |
Psmb1 |
proteasome 20S subunit beta 1 |
multiple interactions |
ISO |
Maneb inhibits the reaction [Paraquat results in decreased expression of PSMB1 mRNA] |
CTD |
PMID:26498265 |
|
NCBI chr 1:56,442,432...56,463,544
Ensembl chr 1:56,420,618...56,463,560
|
|
G |
Psmc4 |
proteasome 26S subunit, ATPase 4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of PSMC4 mRNA] [Paraquat co-treated with Maneb] results in decreased expression of PSMC4 mRNA |
CTD |
PMID:23963992 PMID:26498265 |
|
NCBI chr 1:83,349,127...83,357,497
Ensembl chr 1:83,348,592...83,357,494
|
|
G |
Ptk2b |
protein tyrosine kinase 2 beta |
multiple interactions |
ISO |
[alachlor co-treated with Captan co-treated with Diazinon co-treated with Endosulfan co-treated with mancozeb co-treated with Maneb] results in decreased expression of PTK2B protein modified form |
CTD |
PMID:19883720 |
|
NCBI chr15:40,360,722...40,481,235
Ensembl chr15:40,360,723...40,481,282
|
|
G |
Ptpn4 |
protein tyrosine phosphatase, non-receptor type 4 |
affects activity |
ISO |
Maneb affects the activity of PTPN4 protein |
CTD |
PMID:23611293 |
|
NCBI chr13:30,772,012...30,952,340
Ensembl chr13:30,776,682...30,952,170
|
|
G |
Ptpn9 |
protein tyrosine phosphatase, non-receptor type 9 |
affects activity |
ISO |
Maneb affects the activity of PTPN9 protein |
CTD |
PMID:23611293 |
|
NCBI chr 8:57,391,290...57,472,352
Ensembl chr 8:57,391,259...57,470,952
|
|
G |
Raf1 |
Raf-1 proto-oncogene, serine/threonine kinase |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RAF1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 4:148,679,534...148,740,265
Ensembl chr 4:148,679,530...148,740,317
|
|
G |
Rb1 |
RB transcriptional corepressor 1 |
multiple interactions increases expression |
EXP |
[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA; Acetylcysteine inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RB1 mRNA]; Acetylcysteine inhibits the reaction [Maneb results in increased expression of RB1 mRNA] |
CTD |
PMID:29859004 |
|
NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302
|
|
G |
Rbx1 |
ring-box 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RBX1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:112,976,863...113,001,051
Ensembl chr 7:112,990,835...113,001,051
|
|
G |
Rela |
RELA proto-oncogene, NF-kB subunit |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein; [Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of RELA protein]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased phosphorylation of RELA protein] |
CTD |
PMID:28202386 PMID:29568078 |
|
NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484
|
|
G |
Ripk1 |
receptor interacting serine/threonine kinase 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of RIPK1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr17:30,839,639...30,871,824
Ensembl chr17:30,839,650...30,871,824
|
|
G |
Rock1 |
Rho-associated coiled-coil containing protein kinase 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ROCK1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr18:1,114,532...1,236,345
Ensembl chr18:1,115,905...1,235,571
|
|
G |
Rpl12 |
ribosomal protein L12 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL12 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 3:16,264,269...16,266,645
Ensembl chr 3:16,264,251...16,266,642
|
|
G |
Rpl19 |
ribosomal protein L19 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of RPL19 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:83,022,503...83,026,030
Ensembl chr10:83,019,257...83,052,112
|
|
G |
Rpl41 |
ribosomal protein L41 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL41 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:977,885...978,965
|
|
G |
Rpl8 |
ribosomal protein L8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL8 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:108,626,194...108,628,485
Ensembl chr 7:108,622,324...108,628,482
|
|
G |
Rpl9 |
ribosomal protein L9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPL9 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr14:42,893,945...42,897,140
Ensembl chr14:42,893,942...42,897,136
|
|
G |
Rps12 |
ribosomal protein S12 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS12 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:21,680,854...21,683,010
Ensembl chr 1:21,680,852...21,683,014
|
|
G |
Rps15 |
ribosomal protein S15 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS15 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:9,416,003...9,417,442
Ensembl chr 7:9,416,004...9,417,450
|
|
G |
Rps27 |
ribosomal protein S27 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS27 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 2:175,665,858...175,666,963
Ensembl chr 2:175,665,853...175,666,964
|
|
G |
Rps6ka2 |
ribosomal protein S6 kinase A2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of RPS6KA2 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 1:52,631,582...52,906,739
Ensembl chr 1:52,631,736...52,906,739
|
|
G |
Rtn4 |
reticulon 4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of RTN4 mRNA |
CTD |
PMID:23017109 |
|
NCBI chr14:103,450,074...103,497,687
Ensembl chr14:103,449,930...103,497,686
|
|
G |
Rtn4rl2 |
reticulon 4 receptor-like 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of RTN4RL2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:69,954,557...69,971,108
Ensembl chr 3:69,955,169...69,971,488
|
|
G |
S100a8 |
S100 calcium binding protein A8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of S100A8 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:176,166,517...176,167,645
Ensembl chr 2:176,167,124...176,167,643
|
|
G |
S100a9 |
S100 calcium binding protein A9 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of S100A9 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:176,190,361...176,193,182
Ensembl chr 2:176,190,361...176,193,230
|
|
G |
Scamp2 |
secretory carrier membrane protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SCAMP2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 8:57,965,612...57,992,248
Ensembl chr 8:57,965,631...57,992,646
|
|
G |
Scand1 |
SCAN domain-containing 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SCAND1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:144,818,615...144,819,479
Ensembl chr 3:144,818,611...144,820,025
|
|
G |
Sdhb |
succinate dehydrogenase complex iron sulfur subunit B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SDHB mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293
|
|
G |
Sema4d |
semaphorin 4D |
multiple interactions |
ISO |
[SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA |
CTD |
PMID:23017109 |
|
NCBI chr17:13,430,324...13,537,146
Ensembl chr17:13,430,379...13,537,138
|
|
G |
Sirt1 |
sirtuin 1 |
decreases activity |
ISO |
Maneb results in decreased activity of SIRT1 protein |
CTD |
PMID:21251949 |
|
NCBI chr20:25,307,143...25,329,260
Ensembl chr20:25,306,917...25,329,260
|
|
G |
Sirt2 |
sirtuin 2 |
decreases activity |
ISO |
Maneb results in decreased activity of SIRT2 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:84,053,883...84,076,975
Ensembl chr 1:84,052,903...84,076,975
|
|
G |
Sirt3 |
sirtuin 3 |
decreases activity |
ISO |
Maneb results in decreased activity of SIRT3 protein |
CTD |
PMID:21251949 |
|
NCBI chr 1:195,942,066...195,964,472
Ensembl chr 1:195,942,073...195,964,808
|
|
G |
Slc17a8 |
solute carrier family 17 member 8 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC17A8 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 7:23,994,212...24,049,498
Ensembl chr 7:23,994,217...24,048,079
|
|
G |
Slc18a2 |
solute carrier family 18 member A2 |
multiple interactions decreases expression |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA; Ketoconazole inhibits the reaction [Maneb results in decreased expression of SLC18A2 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC18A2 mRNA] |
CTD |
PMID:18386188 PMID:20964710 PMID:22334051 |
|
NCBI chr 1:258,413,748...258,449,143
Ensembl chr 1:258,413,959...258,448,325
|
|
G |
Slc22a2 |
solute carrier family 22 member 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SLC22A2 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268
|
|
G |
Slc40a1 |
solute carrier family 40 member 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of SLC40A1 protein] |
CTD |
PMID:30797899 |
|
NCBI chr 9:48,033,526...48,053,876
Ensembl chr 9:48,033,526...48,051,481
|
|
G |
Slc5a7 |
solute carrier family 5 member 7 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC5A7 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 9:7,595,440...7,626,258
Ensembl chr 9:7,595,444...7,626,258
|
|
G |
Slc6a2 |
solute carrier family 6 member 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC6A2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr19:14,010,292...14,055,317
Ensembl chr19:14,010,386...14,050,357
|
|
G |
Slc6a3 |
solute carrier family 6 member 3 |
multiple interactions affects response to substance |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of SLC6A3 protein SLC6A3 gene polymorphism affects the susceptibility to Maneb |
CTD |
PMID:11124998 PMID:18386188 PMID:19590691 |
|
NCBI chr 1:29,709,443...29,750,413
Ensembl chr 1:29,709,443...29,750,413
|
|
G |
Slc8a1 |
solute carrier family 8 member A1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of SLC8A1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:13,194,609...13,547,369
Ensembl chr 6:13,194,662...13,535,628
|
|
G |
Snca |
synuclein alpha |
multiple interactions increases response to substance |
ISO |
[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein; [Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]; [Paraquat co-treated with Maneb] results in increased expression of SNCA protein; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ADORA1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of APBB1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of ASCL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of BMP4 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DLL1 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD2 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of DRD5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of HEYL mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of PAX5 mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of SEMA4D mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased phosphorylation of SNCA protein]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of SNCA protein]; SNCA protein inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of CDK5RAP2 mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] promotes the reaction [SNCA protein binds to SNCA protein]] SNCA gene mutant form results in increased susceptibility to Maneb [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased abundance of Nitric Oxide; [Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]] which results in increased metabolism of MEF2C protein; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased abundance of Nitric Oxide; [Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]] which results in increased metabolism of MEF2C protein; Maneb promotes the reaction [Paraquat results in increased expression of SNCA protein]; Maneb promotes the reaction [SNCA gene mutant form results in increased susceptibility to Paraquat]; Paraquat promotes the reaction [SNCA gene mutant form results in increased susceptibility to Maneb]; SNCA protein mutant form results in increased susceptibility to [Paraquat co-treated with Maneb]; SNCA protein results in increased susceptibility to [Maneb co-treated with Paraquat] |
CTD |
PMID:23017109 PMID:24290359 PMID:26498265 PMID:27324791 PMID:29568078 PMID:32375810 PMID:34052309 More...
|
|
NCBI chr 4:89,696,420...89,797,240
Ensembl chr 4:89,696,420...89,796,262
|
|
G |
Sod1 |
superoxide dismutase 1 |
multiple interactions |
ISO EXP |
SOD1 protein results in decreased susceptibility to [Paraquat co-treated with Maneb] [Maneb co-treated with Paraquat] results in increased expression of SOD1 mRNA [Paraquat co-treated with Maneb] results in decreased expression of SOD1 mRNA |
CTD |
PMID:15824117 PMID:18386188 PMID:29859004 |
|
NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249
|
|
G |
Sod2 |
superoxide dismutase 2 |
multiple interactions decreases expression |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SOD2 protein] Maneb results in decreased expression of SOD2 mRNA |
CTD |
PMID:23562983 PMID:26210702 |
|
NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189
|
|
G |
Stat3 |
signal transducer and activator of transcription 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:85,811,206...85,863,057
Ensembl chr10:85,811,218...85,863,057
|
|
G |
Stat4 |
signal transducer and activator of transcription 4 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STAT4 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 9:49,472,660...49,588,540
Ensembl chr 9:49,419,340...49,588,540
|
|
G |
Stmn1 |
stathmin 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of STMN1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr 5:146,680,757...146,687,154
Ensembl chr 5:146,681,436...146,687,154
|
|
G |
Ston2 |
stonin 2 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of STON2 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 6:110,567,485...110,676,376
Ensembl chr 6:110,567,485...110,676,376
|
|
G |
Strbp |
spermatid perinuclear RNA binding protein |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of STRBP mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:21,328,310...21,467,753
Ensembl chr 3:21,337,855...21,414,949
|
|
G |
Sumo1 |
small ubiquitin-like modifier 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of SUMO1 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 9:61,078,790...61,108,697
Ensembl chr 9:61,077,435...61,108,761
|
|
G |
Syt5 |
synaptotagmin 5 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of SYT5 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:69,277,351...69,285,071
Ensembl chr 1:69,277,351...69,285,067
|
|
G |
Tbck |
TBC1 domain containing kinase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TBCK mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 2:221,175,749...221,348,126
Ensembl chr 2:221,175,785...221,348,126
|
|
G |
Tecr |
trans-2,3-enoyl-CoA reductase |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of TECR mRNA |
CTD |
PMID:18386188 |
|
NCBI chr19:24,526,705...24,568,168
Ensembl chr19:24,541,615...24,568,168
|
|
G |
Tgfb1 |
transforming growth factor, beta 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TGFB1 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847
|
|
G |
Th |
tyrosine hydroxylase |
multiple interactions decreases expression |
ISO EXP |
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; [Paraquat co-treated with Maneb] results in decreased expression of TH protein; [Paraquat co-treated with Maneb] results in increased expression of TH protein; Genistein inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Ketoconazole inhibits the reaction [Maneb results in decreased expression of TH protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein]; pimagedine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; prolinedithiocarbamate inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TH protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TH protein] [Paraquat co-treated with Maneb] results in decreased expression of TH; [Paraquat co-treated with Maneb] results in decreased expression of TH mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TH protein |
CTD |
PMID:11124998 PMID:18386188 PMID:20455021 PMID:20964710 PMID:22334051 PMID:24376148 PMID:24486957 PMID:29152652 More...
|
|
NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767
|
|
G |
Timm13 |
translocase of inner mitochondrial membrane 13 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of TIMM13 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:8,809,069...8,810,172
Ensembl chr 7:8,809,058...8,809,910
|
|
G |
Tmem42 |
transmembrane protein 42 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TMEM42 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:122,674,793...122,677,290
Ensembl chr 8:122,674,070...122,677,276
|
|
G |
Tnf |
tumor necrosis factor |
increases expression multiple interactions |
EXP ISO |
Maneb results in increased expression of TNF mRNA [Maneb co-treated with Paraquat] results in increased expression of TNF mRNA; [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; acetovanillone inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; acetovanillone inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Glyburide inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; ITGAM protein affects the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Poloxamer inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNF mRNA]; Taurine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA] [Paraquat co-treated with Maneb] results in increased expression of TNF mRNA; Acetylcysteine inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TNF mRNA]; Silymarin inhibits the reaction [Maneb results in increased expression of TNF mRNA] |
CTD |
PMID:23159886 PMID:23963992 PMID:28202386 PMID:29568078 PMID:30797899 PMID:32169474 PMID:32375810 PMID:34052309 More...
|
|
NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629
|
|
G |
Tnfaip3 |
TNF alpha induced protein 3 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TNFAIP3 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 1:13,709,211...13,724,291
Ensembl chr 1:13,709,206...13,725,282
|
|
G |
Tnr |
tenascin R |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of TNR mRNA |
CTD |
PMID:23017109 |
|
NCBI chr13:71,751,714...72,172,731
Ensembl chr13:72,091,585...72,167,641
|
|
G |
Tp53 |
tumor protein p53 |
multiple interactions |
ISO |
3-bromo-7-nitroindazole inhibits the reaction [[Paraquat co-treated with Maneb] results in increased expression of TRP53 protein]; [Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein; [Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form; [Paraquat co-treated with Maneb] results in increased expression of TRP53 protein; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Melatonin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRP53 mRNA]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in decreased expression of TRP53 protein]; Silymarin inhibits the reaction [[Paraquat co-treated with Maneb] results in increased activity of TRP53 protein modified form] |
CTD |
PMID:20964710 PMID:23963992 PMID:23985028 |
|
NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524
|
|
G |
Traf3ip2 |
Traf3 interacting protein 2 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of ACT1 protein |
CTD |
PMID:23562983 |
|
NCBI chr20:43,011,405...43,054,654
Ensembl chr20:43,011,450...43,054,667
|
|
G |
Traf6 |
TNF receptor associated factor 6 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TRAF6 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 3:87,963,517...87,988,316
Ensembl chr 3:87,963,514...87,983,507
|
|
G |
Trpm3 |
transient receptor potential cation channel, subfamily M, member 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TRPM3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:219,673,200...220,557,610
Ensembl chr 1:219,672,892...220,560,717
|
|
G |
Tuba1a |
tubulin, alpha 1A |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; Minocycline inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of TUBA1A protein] |
CTD |
PMID:23562983 |
|
NCBI chr 7:130,113,214...130,116,880
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tuba1b |
tubulin, alpha 1B |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of TUBA1B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr 7:130,090,669...130,093,644
Ensembl chr 7:130,081,032...130,196,186
|
|
G |
Tubb5 |
tubulin, beta 5 class I |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of TUBB5 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr20:2,912,779...2,916,928
Ensembl chr20:2,912,778...2,916,940
|
|
G |
Tusc1 |
tumor suppressor candidate 1 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of TUSC1 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 5:108,089,952...108,091,636
Ensembl chr 5:108,090,613...108,091,224
|
|
G |
Txn1 |
thioredoxin 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXN1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629
|
|
G |
Txnrd1 |
thioredoxin reductase 1 |
increases expression |
ISO |
[Maneb results in increased expression of NFE2L2 protein] which results in increased expression of TXNRD1 mRNA |
CTD |
PMID:21402726 |
|
NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863
|
|
G |
Uba1 |
ubiquitin-like modifier activating enzyme 1 |
multiple interactions |
ISO |
Maneb results in decreased activity of and results in decreased ubiquitination of UBA1 protein |
CTD |
PMID:25714994 |
|
NCBI chr X:1,508,700...1,530,677
Ensembl chr X:1,508,666...1,530,636
|
|
G |
Ubb |
ubiquitin B |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of UBB mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr10:47,247,629...47,249,335
Ensembl chr10:47,245,637...47,249,333
|
|
G |
Ubc |
ubiquitin C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of UBC mRNA |
CTD |
PMID:18386188 |
|
NCBI chr12:31,238,889...31,243,924
Ensembl chr12:31,239,152...31,243,925
|
|
G |
Ubxn7 |
UBX domain protein 7 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of UBXN7 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr11:68,427,896...68,460,100
|
|
G |
Uchl1 |
ubiquitin C-terminal hydrolase L1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of UCHL1 protein; [Paraquat co-treated with Maneb] results in decreased expression of UCHL1 mRNA |
CTD |
PMID:18386188 PMID:23562983 |
|
NCBI chr14:41,485,033...41,495,590
Ensembl chr14:41,485,031...41,495,590
|
|
G |
Uchl5 |
ubiquitin C-terminal hydrolase L5 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in increased expression of UCHL5 mRNA |
CTD |
PMID:18386188 |
|
NCBI chr13:55,520,722...55,556,503
Ensembl chr13:55,520,729...55,556,502
|
|
G |
Unc13c |
unc-13 homolog C |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of UNC13C mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:74,247,026...74,697,629
Ensembl chr 8:74,247,899...74,673,223
|
|
G |
Upf3b |
UPF3B, regulator of nonsense mediated mRNA decay |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] results in decreased expression of UPF3B mRNA |
CTD |
PMID:18386188 |
|
NCBI chr X:116,335,308...116,353,332
Ensembl chr X:116,335,308...116,353,236
|
|
G |
Uqcrc1 |
ubiquinol-cytochrome c reductase core protein 1 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein; Levodopa inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein]; tetrakis(N-methyl-4-pyridiniumyl)porphine manganese(III) complex inhibits the reaction [[Maneb co-treated with Paraquat] results in increased expression of UQCRC1 protein] |
CTD |
PMID:23562983 |
|
NCBI chr 8:109,589,735...109,601,481
Ensembl chr 8:109,589,706...109,601,480
|
|
G |
Vamp5 |
vesicle-associated membrane protein 5 |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA]; Silymarin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VAMP5 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 4:104,423,813...104,435,059
Ensembl chr 4:104,423,820...104,426,212
|
|
G |
Vegfa |
vascular endothelial growth factor A |
multiple interactions |
ISO |
[LRRK2 protein mutant form co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA; [SNCA protein co-treated with Maneb co-treated with Paraquat] results in decreased expression of VEGFA mRNA |
CTD |
PMID:23017109 |
|
NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641
|
|
G |
Vps45 |
vacuolar protein sorting 45 homolog |
multiple interactions |
ISO |
[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA; Melatonin inhibits the reaction [[Maneb co-treated with Paraquat] results in decreased expression of VPS45 mRNA] |
CTD |
PMID:23963992 |
|
NCBI chr 2:183,555,919...183,616,312
Ensembl chr 2:183,555,921...183,616,295
|
|
G |
Wnt1 |
Wnt family member 1 |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in decreased expression of WNT1 mRNA; [Paraquat co-treated with Maneb] results in decreased expression of WNT1 protein |
CTD |
PMID:29152652 |
|
NCBI chr 7:129,938,604...129,942,651
Ensembl chr 7:129,938,604...129,942,651
|
|
G |
Wnt5a |
Wnt family member 5A |
multiple interactions |
EXP |
[Paraquat co-treated with Maneb] results in increased expression of WNT5A mRNA; [Paraquat co-treated with Maneb] results in increased expression of WNT5A protein |
CTD |
PMID:29152652 |
|
NCBI chr16:3,695,667...3,718,234
Ensembl chr16:3,697,032...3,718,234
|
|
G |
Zbtb44 |
zinc finger and BTB domain containing 44 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ZBTB44 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 8:29,466,055...29,524,027
Ensembl chr 8:29,466,352...29,518,163
|
|
G |
Zfp580 |
zinc finger protein 580 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ZFP580 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 1:68,787,118...68,789,286
Ensembl chr 1:68,787,118...68,789,286
|
|
G |
Zhx3 |
zinc fingers and homeoboxes 3 |
multiple interactions |
ISO |
[Paraquat co-treated with Maneb] affects the expression of ZHX3 mRNA |
CTD |
PMID:22563483 |
|
NCBI chr 3:149,417,843...149,548,671
Ensembl chr 3:149,417,818...149,527,079
|
|
|
G |
Abca5 |
ATP binding cassette subfamily A member 5 |
decreases expression |
ISO |
manganese chloride results in decreased expression of ABCA5 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:95,240,159...95,309,195
Ensembl chr10:95,240,154...95,308,976
|
|
G |
Abca9 |
ATP binding cassette subfamily A member 9 |
increases expression |
ISO |
manganese chloride results in increased expression of ABCA9 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:95,077,615...95,137,751
Ensembl chr10:95,079,058...95,139,608
|
|
G |
Abcb1a |
ATP binding cassette subfamily B member 1A |
increases expression |
EXP |
manganese chloride results in increased expression of ABCB1A mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709
|
|
G |
Abcb1b |
ATP-binding cassette, subfamily B (MDR/TAP), member 1B |
increases expression |
EXP |
manganese chloride results in increased expression of ABCB1B mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:25,242,761...25,325,194
Ensembl chr 4:25,242,798...25,325,199
|
|
G |
Abcc2 |
ATP binding cassette subfamily C member 2 |
increases expression decreases methylation |
EXP |
manganese chloride results in increased expression of ABCC2 mRNA manganese chloride results in decreased methylation of ABCC2 gene |
CTD |
PMID:28801915 |
|
NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238
|
|
G |
Abcc8 |
ATP binding cassette subfamily C member 8 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in increased expression of ABCC8 protein |
CTD |
PMID:32659473 |
|
NCBI chr 1:96,598,663...96,679,495
Ensembl chr 1:96,598,647...96,679,510
|
|
G |
Abi2 |
abl-interactor 2 |
increases expression |
ISO |
manganese chloride results in increased expression of ABI2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 9:61,856,379...61,904,029
Ensembl chr 9:61,827,139...61,905,699
|
|
G |
Abitram |
actin binding transcription modulator |
increases expression |
EXP |
manganese chloride results in increased expression of ABITRAM mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:71,505,853...71,524,224
Ensembl chr 5:71,505,813...71,511,890
|
|
G |
Acap1 |
ArfGAP with coiled-coil, ankyrin repeat and PH domains 1 |
increases expression |
EXP |
manganese chloride results in increased expression of ACAP1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:54,605,323...54,619,472
Ensembl chr10:54,605,323...54,619,472
|
|
G |
Ace |
angiotensin I converting enzyme |
increases expression |
EXP |
manganese chloride results in increased expression of ACE mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131
|
|
G |
Ache |
acetylcholinesterase |
increases activity increases expression multiple interactions decreases activity |
EXP ISO |
manganese chloride results in increased activity of ACHE protein manganese chloride results in increased expression of ACHE mRNA [manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in increased activity of ACHE protein]; [manganese chloride results in increased abundance of Manganese] which results in increased activity of ACHE protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased activity of ACHE protein]; Lycopene inhibits the reaction [manganese chloride results in increased activity of ACHE protein]; Silymarin inhibits the reaction [manganese chloride results in decreased activity of ACHE protein]; Silymarin inhibits the reaction [manganese chloride results in increased activity of ACHE protein]; Silymarin inhibits the reaction [manganese chloride results in increased expression of ACHE mRNA] [manganese chloride results in increased abundance of Manganese] which results in decreased activity of ACHE protein; [manganese chloride results in increased abundance of Manganese] which results in increased activity of ACHE protein; [manganese chloride results in increased abundance of Manganese] which results in increased expression of ACHE mRNA alternative form |
CTD |
PMID:20503066 PMID:22033861 PMID:22154916 PMID:22192907 PMID:30738988 PMID:30844427 PMID:32445656 PMID:33314588 More...
|
|
NCBI chr12:19,407,359...19,413,713
Ensembl chr12:19,407,360...19,413,651
|
|
G |
Aco1 |
aconitase 1 |
increases activity |
EXP |
manganese chloride results in increased activity of ACO1 protein |
CTD |
PMID:15893546 PMID:16545456 PMID:16568477 |
|
NCBI chr 5:55,259,841...55,315,872
Ensembl chr 5:55,259,827...55,316,391
|
|
G |
Aco2 |
aconitase 2 |
multiple interactions decreases expression decreases activity |
ISO EXP |
ferric ammonium citrate inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein] manganese chloride results in decreased expression of ACO2 mRNA; manganese chloride results in decreased expression of ACO2 protein Iron inhibits the reaction [manganese chloride results in decreased activity of ACO2 protein] |
CTD |
PMID:9675333 PMID:16625280 |
|
NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261
|
|
G |
Acot2 |
acyl-CoA thioesterase 2 |
increases expression |
EXP |
manganese chloride results in increased expression of ACOT2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 6:103,611,744...103,619,404
Ensembl chr 6:103,611,544...103,619,245
|
|
G |
Acp5 |
acid phosphatase 5, tartrate resistant |
increases expression increases methylation |
EXP |
manganese chloride results in increased expression of ACP5 mRNA manganese chloride results in increased methylation of ACP5 gene |
CTD |
PMID:22281203 PMID:28801915 |
|
NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:20,663,985...20,667,929
|
|
G |
Acr |
acrosin |
increases expression |
EXP |
manganese chloride results in increased expression of ACR mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 7:120,636,581...120,644,474
Ensembl chr 7:120,638,321...120,644,474
|
|
G |
Acsl3 |
acyl-CoA synthetase long-chain family member 3 |
decreases expression |
ISO |
manganese chloride results in decreased expression of ACSL3 mRNA |
CTD |
PMID:15295902 |
|
NCBI chr 9:80,140,996...80,164,636
Ensembl chr 9:80,115,112...80,164,627
|
|
G |
Acss2 |
acyl-CoA synthetase short-chain family member 2 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ACSS2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:144,003,808...144,047,452
Ensembl chr 3:144,004,336...144,059,675
|
|
G |
Acta1 |
actin, alpha 1, skeletal muscle |
decreases expression |
EXP |
manganese chloride results in decreased expression of ACTA1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr19:51,883,713...51,886,725
Ensembl chr19:51,883,715...51,886,742
|
|
G |
Acta2 |
actin alpha 2, smooth muscle |
increases expression |
EXP |
manganese chloride results in increased expression of ACTA2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554
|
|
G |
Actb |
actin, beta |
decreases expression increases expression |
ISO |
manganese chloride results in decreased expression of ACTB protein manganese chloride results in increased expression of ACTB mRNA |
CTD |
PMID:20452446 |
|
NCBI chr12:11,663,112...11,666,697
Ensembl chr12:11,663,109...11,672,877
|
|
G |
Acvrl1 |
activin A receptor like type 1 |
increases expression |
EXP |
manganese chloride results in increased expression of ACVRL1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 7:132,239,200...132,256,592
Ensembl chr 7:132,239,729...132,256,591
|
|
G |
Adam19 |
ADAM metallopeptidase domain 19 |
increases expression |
EXP |
manganese chloride results in increased expression of ADAM19 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:30,491,362...30,583,115
Ensembl chr10:30,491,405...30,583,105
|
|
G |
Adamts1 |
ADAM metallopeptidase with thrombospondin type 1 motif, 1 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ADAMTS1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr11:24,932,227...24,941,068
Ensembl chr11:24,931,761...24,941,103
|
|
G |
Adamts5 |
ADAM metallopeptidase with thrombospondin type 1 motif, 5 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ADAMTS5 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr11:25,000,627...25,047,205
Ensembl chr11:25,000,637...25,047,205
|
|
G |
Adcy6 |
adenylate cyclase 6 |
increases expression |
EXP |
manganese chloride results in increased expression of ADCY6 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754
|
|
G |
Add2 |
adducin 2 |
increases expression |
EXP |
manganese chloride results in increased expression of ADD2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:118,444,594...118,538,505
Ensembl chr 4:118,497,416...118,538,505
|
|
G |
Adipoq |
adiponectin, C1Q and collagen domain containing |
increases expression |
EXP |
manganese chloride results in increased expression of ADIPOQ mRNA |
CTD |
PMID:28801915 |
|
NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564
|
|
G |
Adm |
adrenomedullin |
increases expression decreases expression |
ISO EXP |
manganese chloride results in increased expression of ADM mRNA manganese chloride results in decreased expression of ADM mRNA |
CTD |
PMID:17175027 PMID:28801915 |
|
NCBI chr 1:164,745,484...164,747,655
Ensembl chr 1:164,745,466...164,747,654
|
|
G |
Adora2a |
adenosine A2a receptor |
increases expression |
EXP |
manganese chloride results in increased expression of ADORA2A mRNA |
CTD |
PMID:28801915 |
|
NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386
|
|
G |
Aen |
apoptosis enhancing nuclease |
increases expression |
EXP |
manganese chloride results in increased expression of AEN mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:132,815,094...132,824,522
Ensembl chr 1:132,815,142...132,824,523
|
|
G |
Aff1 |
ALF transcription elongation factor 1 |
increases expression |
EXP |
manganese chloride results in increased expression of AFF1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr14:5,861,188...6,024,196
Ensembl chr14:5,863,961...6,024,729
|
|
G |
Afmid |
arylformamidase |
increases expression |
EXP |
manganese chloride results in increased expression of AFMID mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:103,046,129...103,061,718
Ensembl chr10:103,046,180...103,061,718
|
|
G |
Afp |
alpha-fetoprotein |
decreases expression |
EXP |
manganese chloride results in decreased expression of AFP mRNA |
CTD |
PMID:26745496 |
|
NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480
|
|
G |
Ahnak2 |
AHNAK nucleoprotein 2 |
increases expression |
EXP |
manganese chloride results in increased expression of AHNAK2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 6:131,830,668...131,876,311
|
|
G |
Aicda |
activation-induced cytidine deaminase |
increases expression |
EXP |
manganese chloride results in increased expression of AICDA mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:155,774,132...155,783,972
Ensembl chr 4:155,774,132...155,783,972
|
|
G |
Aif1 |
allograft inflammatory factor 1 |
increases expression |
ISO |
manganese chloride results in increased expression of AIF1 protein |
CTD |
PMID:28595911 |
|
NCBI chr20:3,646,784...3,652,670
Ensembl chr20:3,646,777...3,652,668
|
|
G |
Akap7 |
A-kinase anchoring protein 7 |
decreases expression |
ISO |
manganese chloride results in decreased expression of AKAP7 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:20,087,190...20,217,799
Ensembl chr 1:20,087,373...20,217,797
|
|
G |
Akr1b1 |
aldo-keto reductase family 1 member B1 |
increases expression |
EXP |
manganese chloride results in increased expression of AKR1B1 mRNA |
CTD |
PMID:22281203 |
|
NCBI chr 4:62,932,033...62,946,126
Ensembl chr 4:62,932,031...62,946,157
|
|
G |
Akt1 |
AKT serine/threonine kinase 1 |
decreases phosphorylation multiple interactions |
EXP ISO |
manganese chloride results in decreased phosphorylation of AKT1 protein NTF3 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of AKT1 protein] [manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of AKT1 protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased phosphorylation of AKT1 protein] |
CTD |
PMID:30040983 PMID:31676349 |
|
NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921
|
|
G |
Alb |
albumin |
multiple interactions |
EXP |
[sodium arsenite co-treated with Cadmium Chloride co-treated with lead acetate co-treated with Mercuric Chloride co-treated with chromium trioxide co-treated with nickel chloride co-treated with manganese chloride co-treated with ferric chloride] results in decreased expression of ALB protein |
CTD |
PMID:17657459 |
|
NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836
|
|
G |
Aldh18a1 |
aldehyde dehydrogenase 18 family, member A1 |
increases expression |
EXP |
manganese chloride results in increased expression of ALDH18A1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:239,375,657...239,407,967
Ensembl chr 1:239,375,669...239,407,890
|
|
G |
Aldh1a1 |
aldehyde dehydrogenase 1 family, member A1 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ALDH1A1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961
|
|
G |
Aldh4a1 |
aldehyde dehydrogenase 4 family, member A1 |
increases expression |
EXP |
manganese chloride results in increased expression of ALDH4A1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:151,880,002...151,905,491
Ensembl chr 5:151,830,701...151,925,345
|
|
G |
Aldoa |
aldolase, fructose-bisphosphate A |
increases expression |
EXP |
manganese chloride results in increased expression of ALDOA mRNA |
CTD |
PMID:22281203 |
|
NCBI chr 1:181,402,275...181,407,476
Ensembl chr 1:181,402,275...181,406,182
|
|
G |
Aldoc |
aldolase, fructose-bisphosphate C |
decreases expression |
EXP |
manganese chloride results in decreased expression of ALDOC mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:63,217,477...63,221,066
Ensembl chr10:63,217,451...63,221,066
|
|
G |
Alkal1 |
ALK and LTK ligand 1 |
increases expression |
EXP |
manganese chloride results in increased expression of ALKAL1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:13,019,729...13,049,913
Ensembl chr 5:13,019,429...13,049,948
|
|
G |
Amigo3 |
adhesion molecule with Ig like domain 3 |
increases expression |
EXP |
manganese chloride results in increased expression of AMIGO3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:108,741,899...108,743,425
Ensembl chr 8:108,693,060...108,744,555
|
|
G |
Angpt2 |
angiopoietin 2 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ANGPT2 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr16:71,088,364...71,138,805
Ensembl chr16:71,088,364...71,138,804
|
|
G |
Angptl4 |
angiopoietin-like 4 |
increases expression |
ISO |
manganese chloride results in increased expression of ANGPTL4 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519
|
|
G |
Ankrd28 |
ankyrin repeat domain 28 |
increases expression |
EXP |
manganese chloride results in increased expression of ANKRD28 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr16:6,918,487...7,050,244
Ensembl chr16:6,914,336...7,050,249
|
|
G |
Ano3 |
anoctamin 3 |
increases expression |
EXP |
manganese chloride results in increased expression of ANO3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:97,238,354...97,550,154
|
|
G |
Anp32a |
acidic nuclear phosphoprotein 32 family member A |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in decreased expression of ANP32A mRNA |
CTD |
PMID:35690225 |
|
Ensembl chr 8:62,827,456...62,865,443
|
|
G |
Anxa3 |
annexin A3 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ANXA3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr14:12,727,708...12,781,717
Ensembl chr14:12,719,795...12,781,617
|
|
G |
Aopep |
aminopeptidase O |
decreases expression |
EXP |
manganese chloride results in decreased expression of AOPEP mRNA |
CTD |
PMID:28801915 |
|
NCBI chr17:1,811,922...2,127,316
Ensembl chr17:1,811,980...2,127,331
|
|
G |
Ap3b2 |
adaptor related protein complex 3 subunit beta 2 |
increases expression |
ISO |
manganese chloride results in increased expression of AP3B2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 1:135,412,580...135,445,191
Ensembl chr 1:135,412,580...135,445,191
|
|
G |
Apbb3 |
amyloid beta precursor protein binding family B member 3 |
increases expression |
EXP |
manganese chloride results in increased expression of APBB3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr18:28,273,168...28,280,347
Ensembl chr18:28,270,545...28,280,094
|
|
G |
Apc |
APC regulator of WNT signaling pathway |
decreases expression increases methylation |
ISO |
manganese chloride results in decreased expression of APC mRNA manganese chloride results in increased methylation of APC gene |
CTD |
PMID:27913844 |
|
NCBI chr18:25,828,558...25,925,511
Ensembl chr18:25,864,222...25,922,696
|
|
G |
Apoa2 |
apolipoprotein A2 |
decreases expression |
EXP |
manganese chloride results in decreased expression of APOA2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355
|
|
G |
Apol2 |
apolipoprotein L, 2 |
increases expression |
ISO |
manganese chloride results in increased expression of APOL2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:109,331,367...109,338,632
Ensembl chr 7:109,331,392...109,338,558
|
|
G |
Apold1 |
apolipoprotein L domain containing 1 |
increases expression |
EXP |
manganese chloride results in increased expression of APOLD1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:167,768,437...167,825,706
Ensembl chr 4:167,818,271...167,825,706
|
|
G |
Aqp3 |
aquaporin 3 (Gill blood group) |
decreases expression |
EXP |
manganese chloride results in decreased expression of AQP3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720
|
|
G |
Areg |
amphiregulin |
increases expression |
EXP |
manganese chloride results in increased expression of AREG mRNA |
CTD |
PMID:28801915 |
|
NCBI chr14:16,972,185...16,981,443
Ensembl chr14:16,972,187...16,981,535
|
|
G |
Arg1 |
arginase 1 |
increases expression increases methylation multiple interactions |
EXP ISO |
manganese chloride results in increased expression of ARG1 mRNA manganese chloride results in increased methylation of ARG1 gene [manganese chloride results in increased abundance of Manganese] which results in increased expression of ARG1 mRNA |
CTD |
PMID:28801915 PMID:34018660 |
|
NCBI chr 1:20,475,878...20,488,422
Ensembl chr 1:20,475,968...20,488,422
|
|
G |
Arhgap24 |
Rho GTPase activating protein 24 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ARHGAP24 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr14:6,800,631...7,184,001
Ensembl chr14:6,800,631...7,183,823
|
|
G |
Arhgdia |
Rho GDP dissociation inhibitor alpha |
decreases expression |
ISO |
manganese chloride results in decreased expression of ARHGDIA mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:105,854,526...105,858,020
Ensembl chr10:105,854,533...105,858,023
|
|
G |
Arhgef10 |
Rho guanine nucleotide exchange factor 10 |
increases expression |
EXP |
manganese chloride results in increased expression of ARHGEF10 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr16:74,647,147...74,738,784
Ensembl chr16:74,647,153...74,738,173
|
|
G |
Arhgef16 |
Rho guanine nucleotide exchange factor 16 |
increases expression |
EXP |
manganese chloride results in increased expression of ARHGEF16 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:164,843,656...164,866,212
Ensembl chr 5:164,844,161...164,866,212
|
|
G |
Arhgef4 |
Rho guanine nucleotide exchange factor 4 |
increases expression increases methylation |
ISO EXP |
manganese chloride results in increased expression of ARHGEF4 mRNA manganese chloride results in increased methylation of ARHGEF4 gene |
CTD |
PMID:17175027 PMID:28801915 |
|
NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:36,861,835...37,005,075
|
|
G |
Arhgef6 |
Rac/Cdc42 guanine nucleotide exchange factor 6 |
increases expression |
EXP |
manganese chloride results in increased expression of ARHGEF6 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr X:135,145,447...135,264,636
Ensembl chr X:135,146,786...135,275,304
|
|
G |
Arhgef7 |
Rho guanine nucleotide exchange factor 7 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ARHGEF7 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr16:77,671,021...77,782,593
Ensembl chr16:77,671,023...77,782,697
|
|
G |
Arid3a |
AT-rich interaction domain 3A |
increases expression |
EXP |
manganese chloride results in increased expression of ARID3A mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 7:9,755,291...9,781,260
Ensembl chr 7:9,755,294...9,780,599
|
|
G |
Arl4c |
ADP ribosylation factor like GTPase 4C |
increases methylation increases expression |
EXP |
manganese chloride results in increased methylation of ARL4C gene manganese chloride results in increased expression of ARL4C mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 9:89,300,335...89,303,770
Ensembl chr 9:89,298,005...89,304,513
|
|
G |
Arnt |
aryl hydrocarbon receptor nuclear translocator |
multiple interactions |
ISO |
ARNT gene mutant form inhibits the reaction [manganese chloride results in increased secretion of VEGFA protein] |
CTD |
PMID:19263519 |
|
NCBI chr 2:182,997,731...183,056,584
Ensembl chr 2:182,997,736...183,056,580
|
|
G |
Asb5 |
ankyrin repeat and SOCS box-containing 5 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ASB5 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr16:37,237,869...37,305,207
Ensembl chr16:37,235,405...37,278,109
|
|
G |
Asns |
asparagine synthetase (glutamine-hydrolyzing) |
increases expression |
EXP |
manganese chloride results in increased expression of ASNS mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423
|
|
G |
Ass1 |
argininosuccinate synthase 1 |
increases expression |
EXP |
manganese chloride results in increased expression of ASS1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:14,747,355...14,796,909
Ensembl chr 3:14,747,368...14,796,903
|
|
G |
Aste1 |
asteroid homolog 1 |
increases expression |
EXP |
manganese chloride results in increased expression of ASTE1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:106,026,570...106,044,694
Ensembl chr 8:106,026,515...106,044,430
|
|
G |
Atf1 |
activating transcription factor 1 |
increases phosphorylation multiple interactions |
EXP |
manganese chloride results in increased phosphorylation of ATF1 protein SB 203580 inhibits the reaction [manganese chloride results in increased phosphorylation of ATF1 protein] |
CTD |
PMID:16787641 |
|
NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670
|
|
G |
Atf2 |
activating transcription factor 2 |
increases activity increases phosphorylation |
ISO |
manganese chloride results in increased activity of ATF2 protein manganese chloride results in increased phosphorylation of ATF2 protein |
CTD |
PMID:19084589 PMID:20152896 |
|
NCBI chr 3:58,718,323...58,795,280
Ensembl chr 3:58,718,332...58,795,236
|
|
G |
Atf4 |
activating transcription factor 4 |
multiple interactions increases expression |
EXP |
manganese chloride promotes the reaction [EIF2AK3 protein results in increased expression of ATF4 mRNA]; SNCA protein promotes the reaction [manganese chloride results in increased expression of ATF4 mRNA] manganese chloride results in increased expression of ATF4 mRNA; manganese chloride results in increased expression of ATF4 protein |
CTD |
PMID:23934647 PMID:23948121 |
|
NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446
|
|
G |
Atf6 |
activating transcription factor 6 |
decreases expression increases expression |
ISO EXP |
manganese chloride results in decreased expression of ATF6 mRNA manganese chloride results in increased expression of ATF6 protein |
CTD |
PMID:17175027 PMID:25732873 |
|
NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177
|
|
G |
Atm |
ATM serine/threonine kinase |
decreases expression |
ISO |
manganese chloride results in decreased expression of ATM mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437
|
|
G |
Atoh8 |
atonal bHLH transcription factor 8 |
decreases expression |
EXP |
manganese chloride results in decreased expression of ATOH8 mRNA |
CTD |
PMID:26745496 PMID:28801915 |
|
NCBI chr 4:104,259,992...104,292,168
Ensembl chr 4:104,259,992...104,292,168
|
|
G |
Atp2a3 |
ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 3 |
increases methylation |
EXP |
manganese chloride results in increased methylation of ATP2A3 gene |
CTD |
PMID:28801915 |
|
NCBI chr10:57,581,742...57,612,758
Ensembl chr10:57,582,128...57,612,748
|
|
G |
Atp2b2 |
ATPase plasma membrane Ca2+ transporting 2 |
increases methylation decreases expression |
ISO |
manganese chloride results in increased methylation of ATP2B2 gene manganese chloride results in decreased expression of ATP2B2 mRNA |
CTD |
PMID:27913844 |
|
NCBI chr 4:146,896,332...147,140,665
Ensembl chr 4:146,896,332...147,140,665
|
|
G |
Atp2b4 |
ATPase plasma membrane Ca2+ transporting 4 |
increases expression |
EXP |
manganese chloride results in increased expression of ATP2B4 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr13:45,156,137...45,255,292
Ensembl chr13:45,156,146...45,255,246
|
|
G |
Atp5f1c |
ATP synthase F1 subunit gamma |
decreases expression |
EXP |
manganese chloride results in decreased expression of ATP5C1 mRNA |
CTD |
PMID:22281203 |
|
NCBI chr17:68,423,927...68,446,169
Ensembl chr17:68,423,909...68,608,367
|
|
G |
Atp6v1a |
ATPase H+ transporting V1 subunit A |
increases expression |
EXP |
manganese chloride results in increased expression of ATP6V1A mRNA |
CTD |
PMID:28801915 |
|
NCBI chr11:56,561,444...56,614,694
Ensembl chr11:56,560,974...56,614,694
|
|
G |
Atp6v1e2 |
ATPase H+ transporting V1 subunit E2 |
decreases expression |
EXP ISO |
manganese chloride results in decreased expression of ATP6V1E2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 6:7,667,359...7,673,711
Ensembl chr 6:7,667,564...7,672,626
|
|
G |
Atp7a |
ATPase copper transporting alpha |
decreases expression affects localization |
EXP |
manganese chloride results in decreased expression of ATP7A mRNA; manganese chloride results in decreased expression of ATP7A protein manganese chloride affects the localization of ATP7A protein |
CTD |
PMID:24614235 |
|
NCBI chr X:71,094,144...71,201,550
Ensembl chr X:71,094,202...71,198,354
|
|
G |
Atp7b |
ATPase copper transporting beta |
affects localization decreases expression |
EXP |
manganese chloride affects the localization of ATP7B protein manganese chloride results in decreased expression of ATP7B mRNA; manganese chloride results in decreased expression of ATP7B protein |
CTD |
PMID:24614235 |
|
NCBI chr16:69,952,286...70,024,404
Ensembl chr16:69,951,778...70,023,636
|
|
G |
Atp8a1 |
ATPase phospholipid transporting 8A1 |
decreases expression |
ISO |
manganese chloride results in decreased expression of ATP8A1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr14:40,315,013...40,557,572
Ensembl chr14:40,315,049...40,554,611
|
|
G |
Avil |
advillin |
decreases expression increases methylation |
EXP |
manganese chloride results in decreased expression of AVIL mRNA manganese chloride results in increased methylation of AVIL gene |
CTD |
PMID:28801915 |
|
NCBI chr 7:62,825,459...62,844,103
Ensembl chr 7:62,826,025...62,844,071
|
|
G |
Axin2 |
axin 2 |
increases expression |
EXP |
manganese chloride results in increased expression of AXIN2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:93,893,830...93,927,042
Ensembl chr10:93,899,245...93,926,231
|
|
G |
Bach1 |
BTB domain and CNC homolog 1 |
increases expression |
EXP |
manganese chloride results in increased expression of BACH1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr11:26,939,429...26,974,876
Ensembl chr11:26,939,480...26,972,447
|
|
G |
Bax |
BCL2 associated X, apoptosis regulator |
increases expression multiple interactions |
EXP ISO |
manganese chloride results in increased expression of BAX mRNA; manganese chloride results in increased expression of BAX protein [manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein; [Plant Extracts co-treated with manganese chloride] affects the expression of BAX protein; benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein]; Estradiol inhibits the reaction [manganese chloride results in increased expression of BAX protein]; Tamoxifen inhibits the reaction [manganese chloride results in increased expression of BAX protein] [manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in increased expression of BAX protein]; [manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein]; manganese chloride results in increased expression of and affects the localization of BAX protein NTF3 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BAX protein] |
CTD |
PMID:17623882 PMID:21704098 PMID:25732873 PMID:26064043 PMID:29183790 PMID:30844427 PMID:30951808 PMID:31676349 PMID:33314588 PMID:35690225 More...
|
|
NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368
|
|
G |
Bcl2 |
BCL2, apoptosis regulator |
decreases expression multiple interactions increases nitrosation increases expression |
EXP ISO |
manganese chloride results in decreased expression of BCL2 mRNA; manganese chloride results in decreased expression of BCL2 protein [manganese chloride results in increased abundance of Manganese] which results in decreased expression of BCL2 protein; [Plant Extracts co-treated with manganese chloride] affects the expression of BCL2 protein; Estradiol inhibits the reaction [manganese chloride results in decreased expression of BCL2 protein]; Tamoxifen inhibits the reaction [manganese chloride results in decreased expression of BCL2 protein] [manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in decreased expression of BCL2 protein]; [manganese chloride results in increased abundance of Manganese] which results in decreased expression of BCL2 protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased expression of BCL2 protein]; manganese chloride results in decreased expression of and affects the localization of BCL2 protein manganese chloride results in increased nitrosation of BCL2 protein corynoxine B inhibits the reaction [manganese chloride promotes the reaction [BCL2 protein binds to BECN1 protein]]; manganese chloride promotes the reaction [BCL2 protein binds to BECN1 protein]; manganese chloride results in increased expression of and results in decreased phosphorylation of BCL2 protein; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [manganese chloride promotes the reaction [BCL2 protein binds to BECN1 protein]]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [manganese chloride results in increased expression of and results in decreased phosphorylation of BCL2 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [manganese chloride results in increased nitrosation of BCL2 protein] manganese chloride results in increased expression of BCL2 mRNA manganese chloride results in increased expression of BCL2 protein |
CTD |
PMID:17623882 PMID:21704098 PMID:25732873 PMID:26064043 PMID:28801915 PMID:28856835 PMID:29183790 PMID:30578841 PMID:30844427 PMID:30951808 PMID:31676349 PMID:33314588 More...
|
|
NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743 Ensembl chr13:22,684,989...22,853,743
|
|
G |
Bcl2l1 |
Bcl2-like 1 |
decreases expression |
EXP |
manganese chloride results in decreased expression of BCL2L1 protein |
CTD |
PMID:27107493 |
|
NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
|
|
G |
Bcl2l11 |
Bcl2-like 11 |
increases expression decreases expression |
EXP |
manganese chloride results in increased expression of BCL2L11 protein manganese chloride results in decreased expression of BCL2L11 mRNA |
CTD |
PMID:25732873 PMID:28801915 |
|
NCBI chr 3:115,366,783...115,404,068
Ensembl chr 3:115,366,646...115,404,068
|
|
G |
Bcl6b |
BCL6B, transcription repressor |
increases expression |
EXP |
manganese chloride results in increased expression of BCL6B mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:54,940,908...54,947,022
Ensembl chr10:54,940,909...54,945,974
|
|
G |
Bdkrb2 |
bradykinin receptor B2 |
increases expression |
EXP |
manganese chloride results in increased expression of BDKRB2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497
|
|
G |
Bdnf |
brain-derived neurotrophic factor |
decreases expression increases expression increases methylation multiple interactions |
ISO EXP |
manganese chloride results in decreased expression of BDNF mRNA manganese chloride results in increased expression of BDNF mRNA manganese chloride results in increased methylation of BDNF gene [manganese chloride results in increased abundance of Manganese] which results in decreased expression of BDNF protein; [manganese chloride results in increased abundance of Manganese] which results in increased expression of BDNF mRNA; CREB1 protein affects the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of BDNF mRNA] |
CTD |
PMID:25698507 PMID:28801915 PMID:30951808 PMID:32659473 |
|
NCBI chr 3:96,165,042...96,215,621
Ensembl chr 3:96,165,042...96,215,615
|
|
G |
Becn1 |
beclin 1 |
increases expression multiple interactions decreases expression affects expression |
EXP ISO |
manganese chloride results in increased expression of BECN1 protein wortmannin inhibits the reaction [manganese chloride results in increased expression of BECN1 protein] manganese chloride results in decreased expression of BECN1 protein corynoxine B affects the reaction [manganese chloride affects the reaction [HMGB1 protein binds to BECN1 protein]]; corynoxine B inhibits the reaction [manganese chloride promotes the reaction [BCL2 protein binds to BECN1 protein]]; manganese chloride affects the reaction [HMGB1 protein binds to BECN1 protein]; manganese chloride promotes the reaction [BCL2 protein binds to BECN1 protein]; N-((3-(aminomethyl)phenyl)methyl)ethanimidamide inhibits the reaction [manganese chloride promotes the reaction [BCL2 protein binds to BECN1 protein]] manganese chloride affects the expression of BECN1 protein |
CTD |
PMID:23604964 PMID:28856835 PMID:30578841 PMID:30672645 |
|
NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742
|
|
G |
Bhlhe40 |
basic helix-loop-helix family, member e40 |
increases expression |
EXP |
manganese chloride results in increased expression of BHLHE40 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774
|
|
G |
Bid |
BH3 interacting domain death agonist |
increases cleavage increases expression multiple interactions |
EXP |
manganese chloride results in increased cleavage of BID protein manganese chloride results in increased expression of BID protein; manganese chloride results in increased expression of BID protein modified form bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased expression of BID protein]; CA 074 methyl ester inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; CA 074 methyl ester inhibits the reaction [manganese chloride results in increased expression of BID protein]; pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein modified form]; pepstatin inhibits the reaction [manganese chloride results in increased expression of BID protein] |
CTD |
PMID:21704098 PMID:28378122 |
|
NCBI chr 4:154,113,198...154,136,353
Ensembl chr 4:154,113,198...154,134,720
|
|
G |
Birc5 |
baculoviral IAP repeat-containing 5 |
multiple interactions decreases expression |
EXP |
Lithium Chloride inhibits the reaction [manganese chloride results in decreased expression of BIRC5 mRNA] |
CTD |
PMID:24464479 |
|
NCBI chr10:103,072,530...103,081,382
Ensembl chr10:103,073,408...103,081,380
|
|
G |
Birc7 |
baculoviral IAP repeat-containing 7 |
increases expression |
EXP |
manganese chloride results in increased expression of BIRC7 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:168,047,824...168,052,606
Ensembl chr 3:168,047,824...168,052,606
|
|
G |
Bloc1s3 |
biogenesis of lysosomal organelles complex-1, subunit 3 |
increases expression |
EXP |
manganese chloride results in increased expression of BLOC1S3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:79,155,914...79,158,326
Ensembl chr 1:79,155,693...79,158,505
|
|
G |
Blvra |
biliverdin reductase A |
increases expression |
EXP |
manganese chloride results in increased expression of BLVRA mRNA |
CTD |
PMID:22281203 |
|
NCBI chr 3:114,340,778...114,366,048
Ensembl chr 3:114,340,838...114,366,033
|
|
G |
Bmal1 |
basic helix-loop-helix ARNT like 1 |
decreases expression |
EXP |
manganese chloride results in decreased expression of BMAL1 mRNA |
CTD |
PMID:28511934 |
|
NCBI chr 1:167,331,756...167,430,235
Ensembl chr 1:167,331,633...167,430,231
|
|
G |
Bmf |
Bcl2 modifying factor |
decreases expression |
EXP |
manganese chloride results in decreased expression of BMF mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145
|
|
G |
Bmp4 |
bone morphogenetic protein 4 |
increases expression |
ISO |
manganese chloride results in increased expression of BMP4 mRNA |
CTD |
PMID:17467022 |
|
NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306
|
|
G |
Bnip3 |
BCL2 interacting protein 3 |
multiple interactions affects response to substance |
ISO |
[N-(3-(aminomethyl)benzyl)acetamidine results in decreased activity of NOS2 protein] inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]; Acetylcysteine inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]; BNIP3 protein affects the reaction [manganese chloride affects the localization of CYCS protein]; Cycloheximide inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]; Dactinomycin inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]; Glutathione inhibits the reaction [manganese chloride results in increased expression of BNIP3 protein]; manganese chloride results in increased expression of and affects the localization of BNIP3 protein BNIP3 protein affects the susceptibility to manganese chloride |
CTD |
PMID:19442826 |
|
NCBI chr 1:193,708,164...193,725,348
Ensembl chr 1:193,708,167...193,725,359
|
|
G |
Bpifb6 |
BPI fold containing family B, member 6 |
increases expression |
EXP |
manganese chloride results in increased expression of BPIFB6 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:142,383,701...142,395,308
Ensembl chr 3:142,381,374...142,395,308
|
|
G |
Bsn |
bassoon (presynaptic cytomatrix protein) |
increases expression |
EXP |
manganese chloride results in increased expression of BSN mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:108,784,849...108,875,819
Ensembl chr 8:108,788,542...108,875,819
|
|
G |
Btnl5 |
butyrophilin-like 5 |
decreases expression |
EXP |
manganese chloride results in decreased expression of BTNL5 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr20:4,366,780...4,376,385
Ensembl chr20:4,365,793...4,376,385
|
|
G |
Btnl7 |
butyrophilin-like 7 |
decreases expression |
EXP |
manganese chloride results in decreased expression of BTNL7 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr20:4,301,078...4,313,522
Ensembl chr20:4,301,854...4,313,274
|
|
G |
Bub1 |
BUB1 mitotic checkpoint serine/threonine kinase |
decreases expression |
ISO |
manganese chloride results in decreased expression of BUB1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 3:115,020,254...115,051,650
Ensembl chr 3:115,020,254...115,051,650
|
|
G |
C1qtnf4 |
C1q and TNF related 4 |
increases expression |
EXP |
manganese chloride results in increased expression of C1QTNF4 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:76,854,368...76,872,991
Ensembl chr 3:76,857,735...76,874,139
|
|
G |
C2cd4b |
C2 calcium-dependent domain containing 4B |
increases expression |
EXP |
manganese chloride results in increased expression of C2CD4B mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:68,372,793...68,396,477
Ensembl chr 8:68,384,847...68,396,328
|
|
G |
C4bpa |
complement component 4 binding protein, alpha |
decreases expression |
EXP |
manganese chloride results in decreased expression of C4BPA mRNA |
CTD |
PMID:28801915 |
|
NCBI chr13:42,075,715...42,111,205
Ensembl chr13:42,075,717...42,111,205
|
|
G |
C5 |
complement C5 |
decreases expression |
EXP |
manganese chloride results in decreased expression of C5 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:18,270,696...18,361,994
Ensembl chr 3:18,270,696...18,361,994
|
|
G |
Cables1 |
Cdk5 and Abl enzyme substrate 1 |
decreases expression |
EXP |
manganese chloride results in decreased expression of CABLES1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr18:3,076,556...3,181,183
Ensembl chr18:3,075,524...3,181,181
|
|
G |
Calcoco2 |
calcium binding and coiled-coil domain 2 |
increases expression |
ISO |
manganese chloride results in increased expression of CALCOCO2 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr10:81,055,467...81,069,298
|
|
G |
Cald1 |
caldesmon 1 |
increases expression |
EXP |
manganese chloride results in increased expression of CALD1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:63,265,781...63,446,936
Ensembl chr 4:63,265,942...63,446,932
|
|
G |
Caly |
calcyon neuron-specific vesicular protein |
increases expression |
EXP |
manganese chloride results in increased expression of CALY mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551
|
|
G |
Camkk2 |
calcium/calmodulin-dependent protein kinase kinase 2 |
increases expression |
ISO |
manganese chloride results in increased expression of CAMKK2 mRNA |
CTD |
PMID:15295902 |
|
NCBI chr12:33,791,023...33,845,000
Ensembl chr12:33,791,052...33,843,279
|
|
G |
Camkv |
CaM kinase-like vesicle-associated |
decreases expression |
EXP |
manganese chloride results in decreased expression of CAMKV mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:108,626,821...108,641,169
Ensembl chr 8:108,626,821...108,641,169
|
|
G |
Camp |
cathelicidin antimicrobial peptide |
increases expression |
EXP |
manganese chloride results in increased expression of CAMP mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:109,841,729...109,843,543
Ensembl chr 8:109,841,729...109,843,543
|
|
G |
Camta2 |
calmodulin binding transcription activator 2 |
increases expression |
EXP |
manganese chloride results in increased expression of CAMTA2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:55,383,450...55,401,838
Ensembl chr10:55,383,450...55,401,558
|
|
G |
Capn5 |
calpain 5 |
increases expression |
EXP |
manganese chloride results in increased expression of CAPN5 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:152,416,252...152,472,923
Ensembl chr 1:152,416,252...152,472,923
|
|
G |
Car5b |
carbonic anhydrase 5B |
decreases expression |
EXP |
manganese chloride results in decreased expression of CAR5B mRNA |
CTD |
PMID:28801915 |
|
NCBI chr X:30,474,697...30,534,797
Ensembl chr X:30,474,784...30,533,837
|
|
G |
Car8 |
carbonic anhydrase 8 |
increases expression |
EXP |
manganese chloride results in increased expression of CAR8 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 5:21,302,940...21,402,395
Ensembl chr 5:21,305,383...21,402,374
|
|
G |
Card14 |
caspase recruitment domain family, member 14 |
increases methylation |
ISO |
manganese chloride results in increased methylation of CARD14 gene |
CTD |
PMID:27913844 |
|
NCBI chr10:104,572,059...104,601,606
Ensembl chr10:104,566,424...104,601,905
|
|
G |
Card9 |
caspase recruitment domain family, member 9 |
decreases expression |
EXP |
manganese chloride results in decreased expression of CARD9 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:9,171,814...9,180,310
Ensembl chr 3:9,171,815...9,180,237
|
|
G |
Casp12 |
caspase 12 |
multiple interactions increases expression increases cleavage |
ISO EXP |
Deferoxamine promotes the reaction [manganese chloride results in increased cleavage of and results in increased activity of CASP12 protein]; manganese chloride results in increased cleavage of and results in increased activity of CASP12 protein manganese chloride results in increased expression of CASP12 mRNA; manganese chloride results in increased expression of CASP12 protein SNCA protein promotes the reaction [manganese chloride results in increased expression of CASP12 protein] manganese chloride results in increased cleavage of CASP12 protein Plant Extracts inhibits the reaction [manganese chloride results in increased cleavage of CASP12 protein] |
CTD |
PMID:23764342 PMID:23934647 PMID:23948121 PMID:25732873 PMID:26064043 PMID:28801915 More...
|
|
NCBI chr 8:2,642,296...2,669,549
Ensembl chr 8:2,642,434...2,674,037
|
|
G |
Casp2 |
caspase 2 |
increases expression |
EXP |
manganese chloride results in increased expression of CASP2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:71,149,632...71,167,388
Ensembl chr 4:71,149,669...71,167,379
|
|
G |
Casp3 |
caspase 3 |
increases cleavage multiple interactions increases expression increases activity increases methylation |
ISO EXP |
manganese chloride results in increased cleavage of CASP3 protein [manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in increased expression of CASP3 protein]; [manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein; [manganese chloride results in increased abundance of Manganese] which results in increased expression of CASP3 protein; Acetylcysteine inhibits the reaction [manganese chloride results in increased expression of CASP3 protein modified form]; bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; CA 074 methyl ester inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased expression of CASP3 protein]; GW 506033X inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; Lithium Chloride inhibits the reaction [manganese chloride results in increased activity of CASP3 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; pyrazolanthrone inhibits the reaction [manganese chloride results in increased expression of CASP3 protein]; Quercetin inhibits the reaction [manganese chloride results in increased activity of CASP3 protein]; rhodioloside inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein]; U 0126 inhibits the reaction [manganese chloride results in increased expression of CASP3 mRNA]; U 0126 inhibits the reaction [manganese chloride results in increased expression of CASP3 protein] manganese chloride results in increased expression of CASP3 mRNA; manganese chloride results in increased expression of CASP3 protein; manganese chloride results in increased expression of CASP3 protein modified form [manganese chloride results in increased abundance of Manganese] which results in increased cleavage of CASP3 protein; Plant Extracts inhibits the reaction [manganese chloride results in increased cleavage of CASP3 protein]; PRNP protein inhibits the reaction [manganese chloride results in increased activity of CASP3 protein] Deferoxamine promotes the reaction [manganese chloride results in increased activity of CASP3 protein]; SNCA protein inhibits the reaction [manganese chloride results in increased activity of CASP3 protein] manganese chloride results in increased methylation of CASP3 gene |
CTD |
PMID:16787641 PMID:17483122 PMID:18178165 PMID:19815061 PMID:23764342 PMID:24464479 PMID:25416158 PMID:25732873 PMID:26064043 PMID:27913844 PMID:28040552 PMID:28378122 PMID:28778520 PMID:30844427 PMID:30991096 PMID:31676349 PMID:32574669 PMID:33314588 More...
|
|
NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648
|
|
G |
Casp4 |
caspase 4 |
increases expression |
EXP |
manganese chloride results in increased expression of CASP4 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:2,599,017...2,635,097
Ensembl chr 8:2,598,876...2,635,092
|
|
G |
Casp8 |
caspase 8 |
increases cleavage multiple interactions |
EXP |
manganese chloride results in increased cleavage of CASP8 protein bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein]; CA 074 methyl ester inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP8 protein] |
CTD |
PMID:21704098 PMID:28378122 |
|
NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542
|
|
G |
Casp9 |
caspase 9 |
increases activity multiple interactions increases cleavage |
ISO EXP |
manganese chloride results in increased activity of CASP9 protein PRNP protein inhibits the reaction [manganese chloride results in increased activity of CASP9 protein] SNCA protein inhibits the reaction [manganese chloride results in increased activity of CASP9 protein] manganese chloride results in increased cleavage of CASP9 protein bafilomycin A1 inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein]; CA 074 methyl ester inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein]; pepstatin inhibits the reaction [manganese chloride results in increased cleavage of CASP9 protein] |
CTD |
PMID:16787641 PMID:17483122 PMID:21704098 PMID:25416158 PMID:28378122 |
|
NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626
|
|
G |
Cat |
catalase |
decreases activity multiple interactions decreases expression |
EXP ISO |
manganese chloride results in decreased activity of CAT protein [manganese chloride results in increased abundance of Manganese] which results in decreased activity of CAT protein; [Plant Extracts co-treated with manganese chloride] results in increased expression of CAT protein; Estradiol inhibits the reaction [manganese chloride results in decreased expression of CAT protein]; Tamoxifen inhibits the reaction [manganese chloride results in decreased expression of CAT protein] [manganese chloride results in increased abundance of Manganese] promotes the reaction [Ethanol results in decreased activity of CAT protein]; [manganese chloride results in increased abundance of Manganese] which results in decreased activity of CAT protein; Ethanol promotes the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased activity of CAT protein]; Quercetin inhibits the reaction [manganese chloride results in decreased activity of CAT protein]; Silymarin inhibits the reaction [manganese chloride results in decreased activity of CAT protein] |
CTD |
PMID:20503066 PMID:22033861 PMID:22192907 PMID:26064043 PMID:28040552 PMID:29183790 PMID:30844427 PMID:32445656 PMID:33314588 More...
|
|
NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478
|
|
G |
Catip |
ciliogenesis associated TTC17 interacting protein |
increases expression |
EXP |
manganese chloride results in increased expression of CATIP mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 9:75,945,933...75,953,618
Ensembl chr 9:75,945,961...75,953,607
|
|
G |
Catsperd |
cation channel sperm associated auxiliary subunit delta |
increases expression |
EXP |
manganese chloride results in increased expression of CATSPERD mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 9:1,459,967...1,498,342
Ensembl chr 9:1,460,001...1,498,344
|
|
G |
Cav2 |
caveolin 2 |
decreases expression |
EXP |
manganese chloride results in decreased expression of CAV2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 4:45,616,766...45,624,144
Ensembl chr 4:45,616,712...45,624,244
|
|
G |
Cbarp |
CACN subunit beta associated regulatory protein |
increases expression |
EXP |
manganese chloride results in increased expression of DOS mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 7:9,566,637...9,575,204
Ensembl chr 7:9,566,364...9,575,204
|
|
G |
Cbs |
cystathionine beta synthase |
decreases expression |
EXP |
manganese chloride results in decreased expression of CBS mRNA |
CTD |
PMID:28801915 |
|
NCBI chr20:9,708,089...9,732,623
Ensembl chr20:9,708,090...9,732,764
|
|
G |
Ccdc15 |
coiled-coil domain containing 15 |
increases expression |
EXP |
manganese chloride results in increased expression of CCDC15 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:36,991,147...37,068,849
Ensembl chr 8:36,998,867...37,068,919
|
|
G |
Ccdc175 |
coiled-coil domain containing 175 |
increases expression |
EXP |
manganese chloride results in increased expression of CCDC175 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 6:90,661,948...90,745,015
Ensembl chr 6:90,662,269...90,744,963
|
|
G |
Ccdc96 |
coiled-coil domain containing 96 |
increases expression |
EXP |
manganese chloride results in increased expression of CCDC96 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr14:74,276,568...74,279,072
Ensembl chr14:74,276,960...74,278,888
|
|
G |
Ccl17 |
C-C motif chemokine ligand 17 |
increases expression |
EXP |
manganese chloride results in increased expression of CCL17 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr19:10,202,317...10,203,768
Ensembl chr19:10,202,128...10,203,819
|
|
G |
Ccl19 |
C-C motif chemokine ligand 19 |
increases expression |
EXP |
manganese chloride results in increased expression of CCL19 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:56,963,364...56,965,308
Ensembl chr 5:56,963,364...56,965,308
|
|
G |
Ccl2 |
C-C motif chemokine ligand 2 |
multiple interactions decreases secretion |
ISO EXP |
manganese chloride inhibits the reaction [CCL2 protein results in increased expression of ICAM1 protein]; manganese chloride inhibits the reaction [Glucose results in increased secretion of CCL2 protein] manganese chloride results in decreased secretion of CCL2 protein |
CTD |
PMID:23329836 |
|
NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226
|
|
G |
Ccl5 |
C-C motif chemokine ligand 5 |
increases expression |
EXP |
manganese chloride results in increased expression of CCL5 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:68,322,826...68,327,365
Ensembl chr10:68,322,829...68,327,377
|
|
G |
Ccl7 |
C-C motif chemokine ligand 7 |
increases expression |
ISO EXP |
manganese chloride results in increased expression of CCL7 mRNA |
CTD |
PMID:17175027 PMID:28801915 |
|
NCBI chr10:67,016,446...67,018,296
Ensembl chr10:67,016,446...67,018,303
|
|
G |
Ccn2 |
cellular communication network factor 2 |
increases expression increases methylation |
ISO EXP |
manganese chloride results in increased expression of CCN2 mRNA manganese chloride results in increased methylation of CCN2 gene |
CTD |
PMID:17467022 PMID:28801915 |
|
NCBI chr 1:20,802,199...20,805,315
Ensembl chr 1:20,802,199...20,805,734
|
|
G |
Ccna1 |
cyclin A1 |
increases expression |
EXP |
manganese chloride results in increased expression of CCNA1 mRNA |
CTD |
PMID:26745496 |
|
NCBI chr 2:139,231,738...139,278,066
Ensembl chr 2:139,201,074...139,243,157
|
|
G |
Ccnb1 |
cyclin B1 |
multiple interactions |
ISO |
[manganese chloride results in increased abundance of Manganese] which results in decreased expression of CCNB1 mRNA; [manganese chloride results in increased abundance of Manganese] which results in decreased expression of CCNB1 protein |
CTD |
PMID:34822792 |
|
NCBI chr 2:31,912,190...31,921,163
Ensembl chr 2:31,912,193...31,921,172
|
|
G |
Ccnb2 |
cyclin B2 |
decreases expression multiple interactions |
ISO |
manganese chloride results in decreased expression of CCNB2 mRNA [manganese chloride results in increased abundance of Manganese] which results in decreased expression of CCNB2 mRNA; [manganese chloride results in increased abundance of Manganese] which results in decreased expression of CCNB2 protein; YTHDC2 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased expression of CCNB2 mRNA]; YTHDC2 protein inhibits the reaction [[manganese chloride results in increased abundance of Manganese] which results in decreased expression of CCNB2 protein] |
CTD |
PMID:17175027 PMID:34822792 |
|
NCBI chr 8:71,087,594...71,100,794
Ensembl chr 8:71,087,595...71,100,874
|
|
G |
Ccng1 |
cyclin G1 |
increases expression |
EXP |
manganese chloride results in increased expression of CCNG1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641
|
|
G |
Cd28 |
Cd28 molecule |
multiple interactions |
ISO |
[manganese chloride co-treated with LCK protein] results in increased phosphorylation of CD28 protein; manganese chloride promotes the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of CD28 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [[manganese chloride co-treated with LCK protein] results in increased phosphorylation of CD28 protein] |
CTD |
PMID:8662792 |
|
NCBI chr 9:62,166,324...62,194,674
Ensembl chr 9:62,166,192...62,194,685
|
|
G |
Cd44 |
CD44 molecule (Indian blood group) |
increases expression |
EXP |
manganese chloride results in increased expression of CD44 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620
|
|
G |
Cd48 |
Cd48 molecule |
increases expression |
ISO |
manganese chloride results in increased expression of CD48 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr13:84,184,884...84,209,144
Ensembl chr13:84,185,532...84,209,142
|
|
G |
Cd6 |
Cd6 molecule |
decreases expression |
EXP |
manganese chloride results in decreased expression of CD6 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:207,442,873...207,481,703
Ensembl chr 1:207,442,877...207,481,634
|
|
G |
Cd74 |
CD74 molecule |
increases expression |
EXP |
manganese chloride results in increased expression of CD74 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr18:54,256,757...54,266,003
Ensembl chr18:54,256,778...54,266,003
|
|
G |
Cd86 |
CD86 molecule |
increases expression |
ISO |
manganese chloride results in increased expression of CD86 protein |
CTD |
PMID:15737199 |
|
NCBI chr11:64,142,193...64,200,816
Ensembl chr11:64,163,828...64,200,818
|
|
G |
Cd8b |
CD8 subunit beta |
increases expression |
ISO |
manganese chloride results in increased expression of CD8B mRNA; manganese chloride results in increased expression of CD8B1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 4:103,312,596...103,328,523
Ensembl chr 4:103,312,578...103,328,553
|
|
G |
Cdc42ep3 |
CDC42 effector protein 3 |
increases expression |
EXP |
manganese chloride results in increased expression of CDC42EP3 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 6:15,710,894...15,731,366
Ensembl chr 6:15,708,730...15,732,721
|
|
G |
Cdhr4 |
cadherin-related family member 4 |
decreases expression |
EXP |
manganese chloride results in decreased expression of CDHR4 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 8:108,682,594...108,690,358
Ensembl chr 8:108,682,613...108,690,367
|
|
G |
Cdkn1a |
cyclin-dependent kinase inhibitor 1A |
multiple interactions increases expression affects localization |
EXP |
Cycloheximide inhibits the reaction [manganese chloride results in increased expression of CDKN1A protein] manganese chloride results in increased expression of CDKN1A mRNA; manganese chloride results in increased expression of CDKN1A protein manganese chloride affects the localization of CDKN1A protein |
CTD |
PMID:22542671 PMID:28801915 |
|
NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585
|
|
G |
Cdkn1c |
cyclin-dependent kinase inhibitor 1C |
decreases expression |
EXP |
manganese chloride results in decreased expression of CDKN1C mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 1:198,655,394...198,658,097
Ensembl chr 1:198,655,407...198,658,048
|
|
G |
Cdkn2b |
cyclin-dependent kinase inhibitor 2B |
increases expression |
EXP |
manganese chloride results in increased expression of CDKN2B mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050
|
|
G |
Cdkn2c |
cyclin-dependent kinase inhibitor 2C |
decreases expression |
ISO |
manganese chloride results in decreased expression of CDKN2C mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 5:124,411,123...124,416,278
Ensembl chr 5:124,411,124...124,416,278
|
|
G |
Cdkn3 |
cyclin-dependent kinase inhibitor 3 |
decreases expression |
ISO |
manganese chloride results in decreased expression of CDKN3 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr15:20,022,522...20,033,948
Ensembl chr15:20,022,664...20,033,945
|
|
G |
Cdnf |
cerebral dopamine neurotrophic factor |
increases expression |
EXP |
manganese chloride results in increased expression of CDNF mRNA |
CTD |
PMID:28801915 |
|
NCBI chr17:74,714,564...74,728,639
Ensembl chr17:74,713,564...74,728,639
|
|
G |
Cdyl2 |
chromodomain Y-like 2 |
increases expression |
EXP |
manganese chloride results in increased expression of CDYL2 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr19:44,591,734...44,783,258
Ensembl chr19:44,597,459...44,783,022
|
|
G |
Cebpd |
CCAAT/enhancer binding protein delta |
increases expression |
ISO |
manganese chloride results in increased expression of CEBPD mRNA |
CTD |
PMID:17175027 |
|
NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829
|
|
G |
Celsr1 |
cadherin, EGF LAG seven-pass G-type receptor 1 |
increases expression |
ISO |
manganese chloride results in increased expression of CELSR1 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 7:116,987,616...117,125,035
Ensembl chr 7:116,987,605...117,125,164
|
|
G |
Cep112 |
centrosomal protein 112 |
increases expression |
EXP |
manganese chloride results in increased expression of CEP112 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr10:93,366,059...93,833,133
Ensembl chr10:93,366,136...93,833,131
|
|
G |
Cep128 |
centrosomal protein 128 |
decreases expression |
ISO |
manganese chloride results in decreased expression of CEP128 mRNA |
CTD |
PMID:17175027 |
|
NCBI chr 6:109,951,009...110,328,686
Ensembl chr 6:109,951,061...110,328,713
|
|
G |
Cers1 |
ceramide synthase 1 |
increases expression |
EXP |
manganese chloride results in increased expression of CERS1 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr16:19,097,309...19,112,519
Ensembl chr16:19,104,466...19,112,519
|
|
G |
Cers6 |
ceramide synthase 6 |
increases expression |
EXP |
manganese chloride results in increased expression of CERS6 mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 3:53,630,636...53,879,692
Ensembl chr 3:53,630,959...53,876,848
|
|
G |
Cflar |
CASP8 and FADD-like apoptosis regulator |
increases expression |
EXP |
manganese chloride results in increased expression of CFLAR mRNA |
CTD |
PMID:28801915 |
|
NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034
|